1CURRICULUM VITAE

CARLO GAMBACORTI-PASSERINI MD

Date of birth: August 26, 1957 Milano - Italy

Mailing address: University of Milano Bicocca,

Dept. of Internal MedicineVia Cadore 48, 20052 Monza

Telephone: 39.039.233-3539 (office/fax)39.02.8811 (beeper)

E-mail Carlo.Gambacorti@unimib.it

Bibliometrics: h-index: 64; g-index: 166; e-index: 184.14; hc-index: 44; hI, norm: 34

EDUCATION

1.1990-6.1991 Clinical Oncology Fellowship, University of Wisconsin Clinical Cancer Center, Madison

WI - USA

11.1982-11.1985 Fellowship in Oncology, Milan University, School of Medicine.

10-1976-10.1982 M.D., Milan University School of Medicine; this includes a two year internship in

internal medicine (1979-81) and a six month rotation (Med/Ped/Gyn, 1982)

1976 B.A., Liceo B. Zucchi, Monza.

RESEARCH/PROFESSIONAL EXPERIENCE

03-2017 Director, Dept of Hematology, S. Gerardo Hospital, Monza and University of Milano Bicocca

03-2014- Director, Post Graduate School of Hematology, University of Milano Bicocca, Monza, Italy02-2014- Professor of Hematology, University of Milano Bicocca, Department of Clinical Medicine,

Section of Hematology, San Gerardo Hospital, Monza, Italy06-200802-2014 Director, Post Graduate School of Medical Oncology, University of Milano Bicocca, Monza,

Italy

12.2007- Director, Clinical Research Unit, San Gerardo Hospital, Monza, Italy2-201712.2006- Consultant, Hematology Service, San Gerardo Hospital, Monza, Italy

11.2006- Professor of internal Medicine, University of Milano Bicocca, Department of Clinical Medicine, Section of Hematology, San Gerardo Hospital, Monza, Italy

12.2003-06.2007 Professor of Molecular Oncology, McGill University, and Canada Research Chair, Montreal,

Canada

8.1998-2.2004 Director, Oncogenic Fusion Proteins Unit, Dept. of Experimental Oncology, Istituto

Nazionale Tumori, Milano - Italy.

12.1996-2.2004 Honorary Consultant, Section of Hematology, University of Milan, S. Gerardo Hospital,

Monza, Italy.

1.1995-7.98 Senior Investigator (tenured), Division of Experimental Oncology D, Istituto Nazionale Tumori, Milano - Italy.

7.1994- Professor of Molecular Oncology/Hematology, University of Heidelberg, and12.1994 Director, Clinical Research Unit, German Cancer Research Center (DKFZ),

Heidelberg, Germany.

6.1991- Senior Investigator (tenured), Division of Experimental Oncology D, Istituto 8.1994Nazionale Tumori, Milano - Italy.

1.1990- Clinical Oncology Fellow, Department of Human Oncology, University of 6.1991Wisconsin, Madison.

1987-89 Physician, Community Emergency Service for the City of Monza (Milano).

1984-89 Research Fellow, Division of Experimental Oncology D and Pediatric Oncology, Istituto Nazionale Tumori, Milano - Italy.

1982-83 Research: Postdoctoral Fellowship, Laboratory for Haemostasis and Thrombosis Research (Dr M.B. Donati), Mario Negri Institute for Pharmacological Research.

1981-82 Research: Doctoral Thesis ("Lysosomal glycosidases in lymphocytes and plasma of breast cancer patients), Department of Biochemistry, Milan

University School of Medicine.

1979-81 Medical Intern, S. Raffaele Hospital, Milan University, School of Medicine (internal medicine experience under the guidance of prof. C. Rugarli).

PRESENT RESEARCH AREA

- Identification of genetic alterations in leukemias through High Throughput Sequencing

- Functional inhibition of oncogenic fusion proteins with tyrosine kinase activity using small molecules.

- Identification and targeting of specific genetic abnormalities in hematological and solid cancers.

CERTIFICATIONS

9.2003 Restrictive permit to practice medicine in Quebec

9.1994 Registration of medical licence in the state of Baden-Wuerttemberg

9.1990 Advanced Cardiac Life Support (ACLS) Certification, American Hearth Association.

8.1989 Educational Commission for Foreign Medical Graduates (ECFMG [U.S.A.]) unrestricted Certification.

11.1988 Test of English as a Foreign Language (TOEFL); 580/677.

1.1988 Foreign Medical Graduates Examination in Medical Sciences (FMGEMS). Basic Sciences, 84/100; Clinical Sciences, 82/100.

11.1985 National Board of Oncology (Italy and EC countries).

12.1982 National Licence to practice medicine (Italy and EC countries).

HONORS & COMMITTEES

2003 Backler Award, McGill University, Montreal, Canada

1995-1999 Editor, Clinical Research/Diagnostics Section, Human Molecular Genetics Network.

1993&1997 Chairman, Selection Committee for the Antonio Castelnuovo Foundation Fellowship Program in Cancer Research.

1990 Italian Association for Cancer Research (AIRC) Fellowship.

1989 NCI-EORTC Exchange Program Fellowship.

1986 AIOM prize for the presentation at the annual meeting of the Italian Association for Medical Oncology.

1982 MD graduation 110/110 summa cum laude.

GRANTS

Awarded:

6/15 EU: ALKTRAS research network: 265 K E

1/15 Berlucchi Foundation: Resistance to ALK inhibitors: 120K E

10/13 AIRC: Molecular Anatomy of aCML: 960K E/3 years

9/12 LORG: Imatinib Stop And Validation trial: 345K €/3 years.

11/11 EU: ALK targeting and molecular mechanisms of resistance: 605K €/2 years

10/10 AIRC grant: HTS in leukemias. 880K €/3 years

09/10 ASTIL grant: development of ALK inhibitors. 300K €/2 years

02/10 CARIPLO grant: molecular analysis of Blast crisis CML, 250K € for 2 years

10/07 Italian Association for Cancer Research (AIRC), individual grant: TARGETING ONCOGENIC FUSION GENES: FROM CML TO PROSTATE CANCER., 160K €/year for 3 years.

07/07 PRIN 2008, 124000.00 E

03/07 CARIPLO Foundation: Fosfoproteomica della Leucemia Mieloide cronica (CML): ruolo della beta-catenina e di altre proteine nella progressione della malattia. 110 K€

03/06 AIFA: LONG TERM EFFECTS OF IMATINIB ADMINISTRATION IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS; 242 K€

01/06 Italian Ministry of Research (COFIN). Delocalizzazione e inibizione di proteine che legano RNA e DNA in linfomi ALK+. 2006-2007, 85K €

06/04 Italian Association for Cancer Research (AIRC), individual grant, 160K €/year for 3 years

03/04 EU, Prokinase Research, 939K €, over 5 years (contr. # 503467), 2004-2008

12/03 Italian Ministry of Research (MIUR) FIRB grant: 49K €

11/03 Italian Ministry of Health (Ricerca Finalizzata 2003): 85K €11.02 Italian Ministry of Health (Ricerca Finalizzata 2002): 45K €

05.02 Italian Research Council (CNR): Molecular Analysis of resistance to STI571. 60K €.

07.01 Italian Ministry of Health (Ricerca Finalizzata): Coordinator: “Inibitori di Proteine di Fusione Oncogeniche Quali Farmaci Innovativi in Oncoematologia”; 305K €

06.01 AIRC (Italian Ass. For Cancer Research) Individual Investigator Grant: 135K € /year for 3 years

02.00 “Molecular analysis of in vitro resistance to a BCR/ABL inhibitor in leukemic cells. José Carreras International Leukemia Foundation, 150,000 USD/3 years

12.99 “In vivo resistance to abl inhibition in BCR/ABL+ human leukemia cells.” European Union 5th Framework Program, Human Capital and Mobility; 153,000 €/2 years.

12.1999 Principal Investigator, “Mechanisms of sensitivity and resistance to retinoic acid in APL Italian Research Council (CNR)/15.000 USD/1 year.

10.99 Member, SPECIFIC TARGETING OF LEUKEMIC CELLS Italian Min. for Research, 60,000 USD year/2 years

12.98 Member, PECIFIC INDUCTION OF APOPTOSIS IN LEUKEMIC AND SOLID TUMOR CELLS Italian Min. for Research, 40,000 USD year/2 years

6.1998 Principal Investigator, PECIFIC TARGETING OF NEOPLASTIC CELLS EXPRESSING ONCOGENIC FUSION PROTEINS (BCR/ABL, PML/RAR , NPM/ALK): IMMUNOLOGIC AND NON-IMMUNOLOGIC APPROACHES Italian Ass. for Cancer Res. Individual Grant/ 120,000 USD year/ 3 years.

6.1998 Principal Investigator, echanisms of sensitivity and resistance to retinoic acid in APL Italian Research Council (CNR)/15.000 USD year.

4.1998 Member, European Union Concerted Action on Peptide sensitization (EUCAPS), Coordinator Graham Pawelec (Tuebingen)/Total amount: 750,000 USD/3 years.

.6.1997 Principal Investigator, echanisms of sensitivity and resistance to retinoic acid in APL

Italian Research Council (CNR)/15.000 USD year.

12.96 European Union Program raining and Mobility of Researchers (TMR) individual award: 105,000 USD/2 years.

10.1996 Member, Italy-USA Program on herapy of Tumors olecular approaches for therapy: inhibition of of the pathological signal transduction triggered by oncogenic fusion proteins in solid tumors. 250,000 USD/ 3 years.

6.1996 Contractor, European Union Shared Cost Action "Nucleic Acid Recognition with emphasis on anti-gene and anti-sense applications. Coordinator Bengt Nord (Goteborg). 80,000 USD/year, duration 3 years.

6.1995 Specific recognition of fusion genes and of their products. Induction of T-cell immunity and targeting of dsDNA and mRNA. Italian Association for Cancer Research (AIRC), 60,000 USD/year, duration 3 years.

6.1995 Molecular analysis of retinoic acid resistance in the acute promyelocytic cell line NB4.306. Italian Research Council, 20,000 USD/year, duration 3 years.

6.1994 "Specific recognition of the pml/RAR gene and protein". 101,900 USD/year Italian Association for Cancer Research (AIRC).

1991 Co-Principal Investigator of a NCI-sponsored clinical trial entitled: "A pilot study of high dose cyclophosphamide in conjunction with recombinant interleukin-2 (rIL-2) and rIL-2 induced peripheral blood mononuclear cells as intensification therapy for poor prognosis, acute nonlymphocytic leukemia."1988 Recipient of a grant (80,000 USD/ 3 years) from the Italian Institute of Health for a project entitled "Generation and characterization of lymphokine activated killers (LAK) resistant cancer cells".

PATENTSUse of pml/RAR fusion peptides as immunogens or immunological reagents. Pat. #

MI92A002675, Italy and EC.

Novartis patent 4-31244, dec. 27, 1999.

Novartis patent EPO# 4-31244, dec. 20, 2000

Immunogenic Alk peptides. US patent 008377, Nov. 15, 2001.

Saggio per l’identificazione di inibitori di ALK, Italian patent. 839680 19/09/02

Immunogenic Alk peptides. PCT application #02/12764, 14/11/2002

Anaplastic Lymphoma Kinase assay, reagents and composition thereof. EPO # 03005186.6, 07/03/03.

Wyeth patent, US, PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER filed Feb. 23, 2008

“Inhibitory compounds of the oncogenic tyrosine kinase ALK”, EPO, filed on March 05, 2008, #EP08006651

“Inhibitory a-carbolines of oncogenic tyrosine kinases”, EP 08015802.5 8-09-2008

MEMBERSHIPSAmerican Society of Hematology (ASH).American Association for Cancer Research (AACR).American Society of Clinical Oncology (ASCO).Italian Association for Cancer Research (SIC).International Ski Instructor Association (ISIA).

ORGANIZATIONS OF INTERNATIONAL CONFERENCES

Imatinib Long Term Effects (ILTE) Study. Final Steering Committee Meeting, Atlanta, USA, December 6 th, 2012

Imatinib Long Term Effects (ILTE) Study. Steering Committee Meeting, San Francisco, USA, December 5 th, 2008

Imatinib Long Term Effects (ILTE) Study. First Scientific Meeting. Atlanta, USA, December 3th, 2007

The Over 10,000 feet CML Meeting, Lagazuoi, February 28th, 2003. The Over 10,000 feet CML Meeting, Theodulpass, March 22, 2002.

1Oncogenic fusion proteins as specific molecular targets for cancer treatment, National Cancer Institute Milano, Italy, May 29th, 1998

Oncogenic fusion proteins as specific molecular targets for cancer treatment, National Cancer Institute Milano, Italy, March 1996.

ORIGINAL PAPERS

1. Gambacorti-Passerini C , Cortes JE, Lipton, JH, Kantarjian, HM, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, Deannuntis L, Brümmendorf TH, Jean Khoury H. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: Final results of a phase I/II study. Haematologica 2018 Aug;103(8):1298-1307. doi: 10.3324/haematol.2017.171249.2. Piazza R, Magistroni V, Redaelli S, Mauri M, Massimino L, Sessa A, Peronaci M, Lalowski M, Soliymani R, Mezzatesta C, Pirola A, Banfi F, Rubio A, Rea D, Stagno F, Usala E, Martino B, Campiotti L, Merli M, Passamonti F, Onida F, Morotti A, Pavesi F, Bregni M, Broccoli V, Baumann

M, and Gambacorti-Passerini C. SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nature Comunications 2018 Jun 6;9(1):2192. doi: 10.1038/s41467-018-04462-8.3. Khoury HJ, Gambacorti-Passerini C, Brummendorf TH. Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Ann Oncol. 2018 Mar;29(3):578-587. doi: 10.1093/annonc/mdy019. 4. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. 5. Clark RE, Gambacorti-Passerini C, Deininger M, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, Le Coutre P, et al. (2018). Efficacy and Safety of First-Line Bosutinib versus Imatinib in the BFORE trial: 18-Month Follow-up. British Journal of Haematology Volume 181, Issue S1:7-8. BSH18-OR-004. doi: 10.1111/bjh.15226.6. Mologni L , Costanza M, Sharma GG, Viltadi M, Massimino L, Citterio S, Purgante S, Raman H, Pirola A, Zucchetti M, Piazza R, Gambacorti-Passerini C . Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. Neoplasia 2018 May;20(5):467-477. doi: 10.1016/j.neo.2018.02.009. 7. Renso R, Aroldi A, Pioltelli P, Gambacorti-Passerini C, Elli EM. Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea. Blood Cancer J. 2018 Jun; 8(6): 56. doi:  10.1038/s41408-018-0091-6.8. Sharma GG, Mota I, Mologni L, Patrucco E, Gambacorti-Passerini C, Chiarle R. Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. Cancers (Basel) 2018 Feb;10(3). pii: E62. doi: 10.3390/cancers10030062.9. Kantarjian HM, Mamolo CM, Gambacorti-Passerini C, Cortes JE, Brummendorf TH, Su Y, Reisman AL, Shapiro M, Lipton JH. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer 2018 Feb;124(3):587-595. doi: 10.1002/cncr.31082. 10. Gambacorti-Passerini C , Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. Am J Hematol. 2018 May;93(5):607-614. doi: 10.1002/ajh.25043. 11. Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brummendorf TH. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J.Clin.Oncol. 2018 Jan; 36(3):231-237. doi: 10.1200/JCO.2017.74.7162.12. Piazza R, Ramazzotti D, Spinelli R, Pirola A, De Sano L, Ferrari P, Magistroni V, Cordani N, Sharma N, Gambacorti-Passerini C. Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes. Sci Rep. 2017 May;7:46823. doi: 10.1038/srep46823.

13. Piazza R, Ramazzotti D, Spinelli R, Pirola A, De Sano L, Ferrari P, Magistroni V, Cordani N, Sharma N, Gambacorti-Passerini C. OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes. Sci Rep. 2017 Apr;7:46290. doi: 10.1038/srep46290.14. Mologni L, Piazza R, Khandelwal P, Pirola A, Gambacorti-Passerini C. Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients. Am J Hematol. 2017 Oct; 92(10):E623-E625. doi: 10.1002/ajh.24865.15. Mologni L, Magistroni V, Casuscelli F, Montemartini M, Gambacorti-Passerini C. The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition. J Cancer. 2017 Jan;8(1):140-145. doi: 10.7150/jca.15838.16. Mologni L, Gambacorti-Passerini C, Goekjian P, Scapozza L. RET kinase inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat. 2017 Jan;27(1):91-99. doi: 10.1080/13543776.2017.1238073. 17. Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, Paquette RL, Simonsson B, Zyczynski T, Foreman A, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Hansen R, Lomaia E, Olavarria E, Mauro MJ. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2017 Nov;92(11):1214-1223. doi: 10.1002/ajh.24887. 18. Gambacorti-Passerini C , Piazza R. How "precise" is precision medicine in hematology? Haematologica January 2017 Volume 102, Issue S1: 4-6; doi:10.3324/haematol.2016.155267.19. Cortes JE, Gambacorti-Passerini C, Kim DW, Kantarjian HM, Lipton JH, Lahoti A, Talpaz M, Matczak E, Barry E, Leip E, Brummendorf TH, Khoury HJ. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):684-695.e6. doi: 10.1016/j.clml.2017.06.001. 20. Campiotti L, Suter MB, Guasti L, Piazza R, Gambacorti-Passerini C, Grandi AM, Squizzato A. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. Eur J Cancer. 2017 May;77:48-56. doi: 10.1016/j.ejca.2017.02.028. 21. Rousselot P, Coude MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, Huguet F, Leguay T, Chevallier P, Salanoubat C, Bonmati C, Alexis M, Hunault M, Glaisner S, Agape P, Berthou C, Jourdan E, Fernandes J, Sutton L, Banos A, Reman O, Lioure B, Thomas X, Ifrah N, Lafage-Pochitaloff M, Bornand A, Morisset L, Robin V, Pfeifer H, Delannoy A, Ribera J, Bassan R, Delord M, Hoelzer D, Dombret H, Ottmann OG, European Working Group on Adult ALL (EWALL) group. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016 Aug;128(6):774-782. doi: 10.1182/blood-2016-02-700153.22. Redaelli S, Ceccon M, Antolini L, Rigolio R, Pirola A, Peronaci M, Gambacorti-Passerini C, Mologni L. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma. Oncotarget. 2016 Nov;7(45):72886-72897. doi: 10.18632/oncotarget.12128.

23. Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ. Chronic myeloid leukemia: reminiscences and dreams. Haematologica. 2016 May;101(5):541-558.doi: 10.3324/haematol.2015.139337.24. Gambacorti-Passerini C , Mussolin L, Brugieres L. Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. N Engl J Med. 2016 Jan;374(1):95-96. doi: 10.1056/NEJMc1511045.25. Gambacorti-Passerini C , Aroldi A, Cordani N, Piazza R. Chronic myeloid leukemia: Second-line drugs of choice. Am J Hematol. 2016 Jan;91(1):67-75. doi: 10.1002/ajh.24247.26. Farina F, Gambacorti-Passerini C.. ALK inhibitors for clinical use in cancer therapy. Front Biosci (Elite Ed). 2016 Jan;8:46-60.doi: 10.2741/E75.27. Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P, Matczak E, Leip E, Noonan K, Brummendorf TH, Gambacorti-Passerini C.. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol. 2016 Dec;91(12):1206-1214. doi: 10.1002/ajh.24536. 28. Cortes JE, Jean Khoury H, Kantarjian H, Brummendorf TH, Mauro MJ, Matczak E, Pavlov D, Aguiar JM, Fly KD, Dimitrov S, Leip E, Shapiro M, Lipton JH, Durand JB, Gambacorti-Passerini C.. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016 Jun;91(6):606-616. doi: 10.1002/ajh.24360. 29. Ceccon M, Merlo MEB, Mologni L, Poggio T, Varesio LM, Menotti M, Bombelli S, Rigolio R, Manazza AD, Di Giacomo F, Ambrogio C, Giudici G, Casati C, Mastini C, Compagno M, Turner SD, Gambacorti-Passerini C, Chiarle R, Voena C. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene. 2016 Jul;35(29):3854-3865. doi: 10.1038/onc.2015.456.30. Caocci G, Greco M, Delogu G, Secchi C, Martino B, Labate C, Abruzzese E, Trawinska MM, Galimberti S, Orru F, Fozza C, Gambacorti Passerini C, Galimi F, La Nasa G. Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients. J Hematol Oncol. 2016 Jul;9(1):63. doi: 10.1186/s13045-016-0293-y.31. Brummendorf TH, Cortes JE, Khoury HJ, Kantarjian HM, Kim DW, Schafhausen P, Conlan MG, Shapiro M, Turnbull K, Leip E, Gambacorti-Passerini C, Lipton JH. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Br J Haematol. 2016 Jan;172(1):97-110. doi: 10.1111/bjh.13801.32. Breccia M, Graffigna G, Galimberti S, Iurlo A, Pungolino E, Pizzuti M, Maggi A, Falzetti F, Capalbo SF, Intermesoli T, Maffioli M, Elena C, Melosi A, Simonetti F, Capochiani E, Seta RD, Pacilli M, Luppi M, Di Renzo N, Mastrullo L, Trabacchi E, Vallisa D, Rapezzi D, Orlandi EM, Gambacorti-Passerini C, Efficace F, Alimena G. Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis. Support Care Cancer. 2016 Nov;24(11):4487-4493. doi: 10.1007/s00520-016-3286-z. 33. Sharma N, Magistroni V, Piazza R, Citterio S, Mezzatesta C, Khandelwal P, Pirola A, Gambacorti-Passerini C.. BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene. Mol Cancer. 2015 Jul;14:132. doi: 10.1186/s12943-015-0407-0.

34. Redaelli S, Perini P, Ceccon M, Piazza R, Rigolio R, Mauri M, Boschelli F, Giannoudis A, Gambacorti-Passerini C.. In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. J Hematol Oncol. 2015 Jul;8:81. doi: 10.1186/s13045-015-0179-4.35. Piazza R, Cecchetti C, Pirola A, Donandoni C, Fontana D, Mezzatesta C, Magistroni V, Bianchi B, Borin L, Fumagalli M, Gambacorti-Passerini C.. RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients. Am J Hematol. 2015 Dec;90(12):E227-228. doi: 10.1002/ajh.24210.36. Muvarak N, Kelley S, Robert C, Baer MR, Perrotti D, Gambacorti-Passerini C, Civin C, Scheibner K, Rassool FV. c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias. Mol Cancer Res. 2015 Apr;13(4):699-712. doi: 10.1158/1541-7786.MCR-14-0422.37. Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, Elena C, Pierri I, Assouline S, D'Emilio A, Gozzini A, Giraldo P, Stagno F, Iurlo A, Luciani M, De Riso G, Redaelli S, Kim DW, Pirola A, Mezzatesta C, Petroccione A, Lodolo D'Oria A, Crivori P, Piazza R, Gambacorti-Passerini C.. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015 Oct;90(10):910-914. doi: 10.1002/ajh.24120.38. Mologni L, Ceccon M, Pirola A, Chiriano G, Piazza R, Scapozza L, Gambacorti-Passerini C.. NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Oncotarget. 2015 Mar;6(8):5720-5734. doi: 10.18632/oncotarget.3122.39. Hoareau-Aveilla C, Valentin T, Daugrois C, Quelen C, Mitou G, Quentin S, Jia J, Spicuglia S, Ferrier P, Ceccon M, Giuriato S, Gambacorti-Passerini C, Brousset P, Lamant L, Meggetto F. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth. J Clin Invest. 2015 Sep;125(9):3505-3518. doi: 10.1172/JCI78488.40. Gambacorti-Passerini CB , Donadoni C, Parmiani A, Pirola A, Redaelli S, Signore G, Piazza V, Malcovati L, Fontana D, Spinelli R, Magistroni V, Gaipa G, Peronaci M, Morotti A, Panuzzo C, Saglio G, Usala E, Kim DW, Rea D, Zervakis K, Viniou N, Symeonidis A, Becker H, Boultwood J, Campiotti L, Carrabba M, Elli E, Bignell GR, Papaemmanuil E, Campbell PJ, Cazzola M, Piazza R. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood. 2015 Jan;125(3):499-503. doi: 10.1182/blood-2014-06-579466.41. Gambacorti-Passerini C , Piazza R. How I treat newly diagnosed chronic myeloid leukemia in 2015. Am J Hematol. 2015 Feb;90(2):156-161. doi: 10.1002/ajh.23887. 42. Gambacorti-Passerini C , Piazza R. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. JAMA Oncol. 2015 May;1(2):143-144. doi: 10.1001/jamaoncol.2015.50.43. Gambacorti-Passerini C , Piazza R. Erratum in: Incorrect Drug Name. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. JAMA Oncol. 2015 May;1(2):255. doi: 10.1001/jamaoncol.2015.1156.44. Gambacorti-Passerini C , Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brummendorf TH, Matczak E, Bardy-Bouxin N, Shapiro M, Turnbull K, Leip E, Cortes JE. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015 Sep;90(9):755-768.

doi: 10.1002/ajh.24034.45. Fontana D, Ceccon M, Gambacorti-Passerini C, Mologni L. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. Cancer Med. 2015 Jul;4(7):953-965. doi: 10.1002/cam4.413.46. Di Savino A, Panuzzo C, Rocca S, Familiari U, Piazza R, Crivellaro S, Carra G, Ferretti R, Fusella F, Giugliano E, Camporeale A, Franco I, Miniscalco B, Cutrin JC, Turco E, Silengo L, Hirsch E, Rege-Cambrin G, Gambacorti-Passerini C, Pandolfi PP, Papotti M, Saglio G, Tarone G, Morotti A, Brancaccio M. Morgana acts as an oncosuppressor in chronic myeloid leukemia. Blood. 2015 Apr;125(14):2245-2253. doi: 10.1182/blood-2014-05-575001. 47. Ceccon M, Mologni L, Giudici G, Piazza R, Pirola A, Fontana D, Gambacorti-Passerini C.. Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma. Mol Cancer Res. 2015 Apr;13(4):775-783. doi: 10.1158/1541-7786.MCR-14-0157.48. Caocci G, Martino B, Greco M, Abruzzese E, Trawinska MM, Lai S, Ragatzu P, Galimberti S, Barate C, Mulas O, Labate C, Littera R, Carcassi C, Gambacorti Passerini C, La Nasa G. Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. Exp Hematol. 2015 Dec;43(12):1015-1018.e1. doi: 10.1016/j.exphem.2015.08.004.49. Brummendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillie L, Pavlov D, Gogat K, Countouriotis AM, Gambacorti-Passerini C.. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015 Jan;168(1):69-81. doi: 10.1111/bjh.13108. 50. Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, De Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Salvi F, Pini M, Leoni P, Rupoli S, Galieni P, Bigazzi C, Cantore N, Palmieri F, Albano F, Russo Rossi A, Rambaldi A, Intermesoli T, Palandri F, Testoni N, Luatti S, Soverini S, Iacobucci I, Bochicchio M, Apolinari M, Fogli M, Cervello I, Capucci A, Malagola M, Malpignano A, Girasoli M, Angelucci E, Usala E, Storti S, De Biasi E, Tagariello G, Sartori R, Di Raimondo F, Vigneri P, Impera S, Molica S, Lanza F, Viganò C, Grasso M, Rapezzi D, Cavazzini F, Bosi A, Santini V, Capalbo S, Spinosa G, Pierri I, Bergamaschi M, Carella A, Bacigalupo A, De Blasio A, Ciccone F, Di Renzo N, Musolino C, Russo S, Cortelezzi A, Morra E, Pungolino E, Luppi M, Marasca R, Pogliani E, Gambacorti-Passerini C, Luciano L, Ferrara F, Annunziata M, Latte G, Noli D, Rege-Cambrin G, Fava C, Semenzato G, Binotto G, Fabbiano F, Turri D, Siragusa S, Caracciolo C, Musso M, Porretto F, Aversa F, Crugnola M, Cazzola M, Orlandi E, Falini B, Falzetti F, Visani G, Isidori A, Fioritoni G, Di Lorenzo R, Vallisa D, Trabacchi E, Petrini M, Galimberti S, Pizzuti M, Zaccaria A, Salvucci M, Ronco F, Ielo D, Merli F, Avanzini P, Tosi P, Merli A, Musto P, De Stefano V, Sica S, Latagliata R, De Fabritiis P, Trawiska M, Majolino I, Pacilli L, Ronci B, Cedrone M, Petti M, Pisani F, Tafuri A, Montefusco E, Iuliano F, Dore F, Pardini S, Bocchia M, Defina M, Liberati A, Luzzi D, Boccadoro M, Ferrero D, Vitolo U, Gherlinzoni F, Calistri E, Fanin R, Pizzolo G, Meneghini V, Rodighiero F, D'Emilio A (2015). Differences among young adults, adults and elderly chronic myeloid leukemia patients. ANNALS OF ONCOLOGY, vol. 26, p. 185-192, ISSN: 0923-7534. doi: 10.1093/annonc/mdu490.51. Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C,

Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M,Gambacorti Passerini C. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152.52. Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, Gobbi M, Carella AM, Gozzini A, Usala E, Cavazzini F, Danise P, Tiribelli M, Binotto G, Pregno P, Bocchia M, Gaidano G, Crugnola M, Bonifacio M, Avanzini P, Celesti F, Guella A, Martino B, Annunziata M, Luciano L, Stagno F, Vallisa D, Pungolino E, Iurlo A, Rambaldi A, Nardiello I, Orlandi E, Gambacorti-Passerini C, Alimena G. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leuk Res. 2015 Oct;39(10):1055-1059. doi: 10.1016/j.leukres.2015.07.004. 53. Vigano I, Di Giacomo N, Bozzani S, Antolini L, Piazza R, Gambacorti Passerini C.. First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis. Am J Hematol. 2014 Oct;89(10):E184-187. doi: 10.1002/ajh.23804. 54. Tardy S, Orsato A, Mologni L, Bisson WH, Donadoni C, Gambacorti-Passerini C, Scapozza L, Gueyrard D, Goekjian PG. Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors. Bioorg Med Chem. 2014 Feb;22(4):1303-1312. doi: 10.1016/j.bmc.2014.01.007.55. Rusconi F, Piazza R, Vagge E, Gambacorti-Passerini C.. Bosutinib: a review of preclinical and clinical studies in chronic myelogenous leukemia. Expert Opin Pharmacother. 2014 Apr;15(5):701-710. doi: 10.1517/14656566.2014.882898.56. Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brummendorf TH, Porkka K, Martinelli G, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C.. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014 Feb;123(9):1309-1318. doi: 10.1182/blood-2013-07-513937. 57. Gambacorti-Passerini C , Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V, Pavlov D, Gogat Marchant K, Duvillie L, Khattry N, Kantarjian HM, Brummendorf TH. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014 Oct;89(10):947-953. doi: 10.1002/ajh.23788. 58. Gambacorti-Passerini C , Brummendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol. 2014 Jul;89(7):732-742. doi: 10.1002/ajh.23728.59. Gambacorti Passerini C , Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, Messa C, Guerra L, Giudici G, Sala E, Mussolin L, Deeren D, King MH, Steurer M, Ordemann R, Cohen AM, Grube M, Bernard L, Chiriano G, Antolini L, Piazza R. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014 Feb;106(2):1-4. doi: 10.1093/jnci/djt378.60. Breccia M, Alimena G, Baccarani M, Bocchia M, Di Raimondo F, Gambacorti-Passerini C, Gozzini A, Morra E, Pane F, Pregno P, Rege-Cambrin G, Rosti G, Specchia G, Vigneri P, Saglio

G. Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. Crit Rev Oncol Hematol. 2014 Jun;90(3):181-189. doi: 10.1016/j.critrevonc.2013.12.010.61. Wege H, Brummendorf TH, Gambacorti-Passerini C.. A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma. Hepatology. 2013 Apr;57(4):1291-1293. doi: 10.1002/hep.26050.62. Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G, Jamieson C, Soverini S, Gambacorti-Passerini C, Hehlmann R, Martinelli G, Perrotti D, Scadden DT, Skorski T, Tefferi A, Mughal TI. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. Leuk Lymphoma. 2013 Jun;54(6):1151-1158. doi: 10.3109/10428194.2012.745524.63. Spinelli R, Pirola A, Redaelli S, Sharma N, Raman H, Valletta S, Magistroni V, Piazza R, Gambacorti-Passerini C.. Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases. Mol Genet Genomic Med. 2013 Nov;1(4):246-259. doi: 10.1002/mgg3.23. 64. Sasibhushan S, CGP, Rao, Ponnuvel KM. Genome wide microarray based expression profiles during early embryogenesis in diapause induced and non-diapause eggs of polyvoltine silkworm Bombyx mori. Genomics. 2013 Oct;102(4):379-387. doi: 10.1016/j.ygeno.2013.07.007. 65. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim DW, Boultwood J, Rossi F, Gaipa G, De Martini GP, di Celle PF, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NC, Gambacorti-Passerini C.. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013 Jan;45(1):18-24. doi: 10.1038/ng.2495. 66. Piazza R, Magistroni V, Pirola A, Redaelli S, Spinelli R, Redaelli S, Galbiati M, Valletta S, Giudici G, Cazzaniga G, Gambacorti-Passerini C.. CEQer: a graphical tool for copy number and allelic imbalance detection from whole-exome sequencing data. PLoS One. 2013 Oct 4;8(10):e74825. doi: 10.1371/journal.pone.0074825.67. Piazza R, Magistroni V, Mogavero A, Andreoni F, Ambrogio C, Chiarle R, Mologni L, Bachmann PS, Lock RB, Collini P, Pelosi G, Gambacorti-Passerini C.. Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex. Neoplasia. 2013 May;15(5):511-522.doi: 10.1593/neo.121784.68. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, Shlien A, Groves MJ, Forbes SA, Raine K, Hinton J, Mudie LJ, McLaren S, Hardy C, Latimer C, Della Porta MG, O'Meara S, Ambaglio I, Galli A, Butler AP, Walldin G, Teague JW, Quek L, Sternberg A, Gambacorti-Passerini C, Cross NC, Green AR, Boultwood J, Vyas P, Hellstrom-Lindberg E, Bowen D, Cazzola M, Stratton MR, Campbell PJ, Chronic Myeloid Disorders Working Group of the International Cancer Genome C. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013 Nov 21;122(22):3616-3627; quiz 3699. doi: 10.1182/blood-2013-08-518886.

69. Mologni L, Redaelli S, Morandi A, Plaza-Menacho I, Gambacorti-Passerini C.. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. Mol Cell Endocrinol. 2013 Sep;377(1-2):1-6. doi: 10.1016/j.mce.2013.06.025. 70. Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, Haferlach T, Schnittger S. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013 Sep;27(9):1852-1860. doi: 10.1038/leu.2013.133. 71. Galvan A, Frullanti E, Anderlini M, Manenti G, Noci S, Dugo M, Ambrogi F, De Cecco L, Spinelli R, Piazza R, Pirola A, Gambacorti-Passerini C, Incarbone M, Alloisio M, Tosi D, Nosotti M, Santambrogio L, Pastorino U, Dragani TA. Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients. Carcinogenesis. 2013 Dec;34(12):2767-2773. doi: 10.1093/carcin/bgt294. 72. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, Investigators P. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov;369(19):1783-1796. doi: 10.1056/NEJMoa1306494. 73. Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C.. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res. 2013 Feb;11(2):122-132. doi: 10.1158/1541-7786.MCR-12-0569.74. Bellisola G, Cinque G, Vezzalini M, Moratti E, Silvestri G, Redaelli S, Gambacorti Passerini C, Wehbe K, Sorio C. Rapid recognition of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy and unsupervised hierarchical cluster analysis. Analyst. 2013 Jul;138(14):3934-3945. doi: 10.1039/c2an36393c.75. Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol. 2012 Nov;87(11):E125-E128. doi: 10.1002/ajh.23338. 76. Piazza R, Pirola A, Spinelli R, Valletta S, Redaelli S, Magistroni V, Gambacorti-Passerini C.. FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery. Nucleic Acids Res. 2012 Sep;40(16):e123. doi: 10.1093/nar/gks394. 77. Luca Mologni, Carlo Gambacorti-Passerini. New developments in the treatment of ALK-driven malignancies. Clinical Investigation. 2012; 2(8): 835–852.doi: 10.4155/CLI.12.67.78. Reddiconto G1, Toto C, Palamà I, De Leo S, de Luca E, De Matteis S, Dini L, Passerini CG, Di Renzo N, Maffia M, Coluccia AM. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells. Blood. 2012 Mar;119(10):2335-2345. doi: 10.1182/blood-2011-06-361261.

79. Mologni L, Brussolo S, Ceccon M, Gambacorti-Passerini C.. Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells. PLoS One. 2012;7(12):e51449. doi: 10.1371/journal.pone.0051449. 80. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Brummendorf TH. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012 Apr;119(15):3403-3412. doi: 10.1182/blood-2011-11-390120. 81. Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L, Malhotra H, Powell C, Gogat K, Countouriotis AM, Gambacorti-Passerini C.. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct;30(28):3486-3492. doi: 10.1200/JCO.2011.38.7522.82. Tartari CJ, Scapozza L, Gambacorti-Passerini C.. The ALK gene, an attractive target for inhibitor development. Curr Top Med Chem. 2011;11(11):1406-1419.doi: 10.2174/156802611795589593.83. Tartari CJ, Donadoni C, Manieri E, Mologni L, Mina PD, Villa A, Gambacorti-Passerini C.. Dissection of the RET/beta-catenin interaction in the TPC1 thyroid cancer cell line. Am J Cancer Res. 2011;1(6):716-725. 84. Plaza-Menacho I, Morandi A, Mologni L, Boender P, Gambacorti-Passerini C, Magee AI, Hofstra RM, Knowles P, McDonald NQ, Isacke CM. Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. J Biol Chem. 2011 May;286(19):17292-17302. doi: 10.1074/jbc.M110.168500.85. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Rapado I, Cvejic A, Rance R, McGee C, Ellis P, Mudie LJ, Stephens PJ, McLaren S, Massie CE, Tarpey PS, Varela I, Nik-Zainal S, Davies HR, Shlien A, Jones D, Raine K, Hinton J, Butler AP, Teague JW, Baxter EJ, Score J, Galli A, Della Porta MG, Travaglino E, Groves M, Tauro S, Munshi NC, Anderson KC, El-Naggar A, Fischer A, Mustonen V, Warren AJ, Cross NC, Green AR, Futreal PA, Stratton MR, Campbell PJ, Chronic Myeloid Disorders Working Group of the International Cancer Genome C. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011 Oct;365(15):1384-1395. doi: 10.1056/NEJMoa1103283. 86. Mughal TI, Radich JP, Van Etten RA, Quintas-Cardama A, Skorski T, Ravandi F, DeAngelo DJ, Gambacorti-Passerini C, Martinelli G, Tefferi A. Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. Am J Hematol. 2011 Sep;86(9):811-819. doi: 10.1002/ajh.22097.87. Marfe G, Di Stefano C, Gambacurta A, Ottone T, Martini V, Abruzzese E, Mologni L, Sinibaldi-Salimei P, de Fabritis P, Gambacorti-Passerini C, Amadori S, Birge RB. Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. Exp Hematol. 2011 Jun;39(6):653-665.e6. doi: 10.1016/j.exphem.2011.02.013. 88. Magistroni V, Mologni L, Sanselicio S, Reid JF, Redaelli S, Piazza R, Viltadi M, Bovo G, Strada G, Grasso M, Gariboldi M, Gambacorti-Passerini C.. ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells. PLoS One. 2011;6(11):e28162. doi: 10.1371/journal.pone.0028162.

89. Gambacorti-Passerini C , Piazza R. Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy. Am J Hematol. 2011 Jul;86(7):531-532. doi: 10.1002/ajh.22084. 90. Gambacorti-Passerini C , Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011 Feb; 364(8):775-776. doi: 10.1056/NEJMc1013224.91. Gambacorti-Passerini C , Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D'Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Piazza R, Valsecchi MG, Kim DW. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011 Apr;103(7):553-561. doi: 10.1093/jnci/djr060. 92. Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C.. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011 Oct;118(17):4567-4576. doi: 10.1182/blood-2011-05-355594. 93. af Gennas GB, Mologni L, Ahmed S, Rajaratnam M, Marin O, Lindholm N, Viltadi M, Gambacorti-Passerini C, Scapozza L, Yli-Kauhaluoma J. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors. ChemMedChem. 2011 Sep;6(9):1680-1692. doi: 10.1002/cmdc.201100168. 94. Yasmeen A, Alachkar A, Dekhil H, Gambacorti-Passerini C, Al Moustafa AE. Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV. J Oncol. 2010; Article ID 530130, 10 pages. doi: 10.1155/2010/530130. 95. Redaelli S, Boschelli F, Perini P, Pirola A, Viltadi M, Gambacorti-Passerini C. Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib. Leukemia. 2010 Jun;24(6):1223-1227. doi: 10.1038/leu.2010.79. 96. Rebora P, Czene K, Antolini L, Gambacorti Passerini C, Reilly M, Valsecchi MG. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol. 2010 Nov;172(9):1028-1033. doi: 10.1093/aje/kwq262. 97. Palama IE, Leporatti S, de Luca E, Di Renzo N, Maffia M, Gambacorti-Passerini C, Rinaldi R, Gigli G, Cingolani R, Coluccia AM. Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells. Nanomedicine (Lond). 2010 Apr;5(3):419-431. doi: 10.2217/nnm.10.8.98. Mologni L, Rostagno R, Brussolo S, Knowles PP, Kjaer S, Murray-Rust J, Rosso E, Zambon A, Scapozza L, McDonald NQ, Lucchini V, Gambacorti-Passerini C. Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb;18(4):1482-1496. doi: 10.1016/j.bmc.2010.01.011. 99. Mologni L, Dekhil H, Ceccon M, Purgante S, Lan C, Cleris L, Magistroni V, Formelli F, Gambacorti-Passerini CB. Colorectal tumors are effectively eradicated by combined inhibition of

{beta}-catenin, KRAS, and the oncogenic transcription factor ITF2. Cancer Res. 2010 Sep 15;70(18):7253-7263. doi: 10.1158/0008-5472.CAN-10-1108. 100. Mariani S, Tornaghi L, Sassone M, Basciani S, Buzzetti R, Gambacorti-Passerini C, Spera G, Gnessi L. Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia. Leuk Res. 2010 Jan;34(1):e5-7. doi: 10.1016/j.leukres.2009.08.003. 101. Marega M, Piazza RG, Pirola A, Redaelli S, Mogavero A, Iacobucci I, Meneghetti I, Parma M, Pogliani EM, Gambacorti-Passerini C. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients. Leukemia. 2010 Aug;24(8):1445-1449. doi: 10.1038/leu.2010.101. 102. Brandt W, Mologni L, Preu L, Lemcke T, Gambacorti-Passerini C, Kunick C. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. Eur J Med Chem. 2010 Jul;45(7):2919-2927. doi: 10.1016/j.ejmech.2010.03.017.103. Boschelli F, Arndt K, Gambacorti-Passerini C. Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia. Eur J Cancer. 2010 Jul;46(10):1781-1789. doi: 10.1016/j.ejca.2010.02.032.104. Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A, Bhadri VA, Szymanska B, Geninson G, Magistroni V, Cazzaniga G, Biondi A, Miranda-Saavedra D, Gottgens B, Saffery R, Craig JM, Marshall GM, Gambacorti-Passerini C, Pimanda JE, Lock RB. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood. 2010 Oct;116(16):3013-3022. doi: 10.1182/blood-2010-05-284968. 105. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, Gambacorti-Passerini C, Boschelli F. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009 Jan;27(3):469-471. doi: 10.1200/JCO.2008.19.8853. 106. Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, Gregorio A, Gambini C, Garaventa A, Pistoia V, Del Grosso F, Tonini GP, Cheng M, Gambacorti-Passerini C, Anichini A, Fossati-Bellani F, Di Nicola M, Luksch R. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 2009 Sep;69(18):7338-7346. doi: 10.1158/0008-5472.CAN-08-4419. 107. Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, Formelli F, Gambacorti-Passerini C. Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. Int J Cancer. 2009 Apr;124(8):1990-1996. doi: 10.1002/ijc.24158.108. Wakata A, Cahill SM, Blumenstein M, Gunby RH, Jockusch S, Marti AA, Cimbro B, Gambacorti-Passerini C, Donella-Deana A, Pinna LA, Turro NJ, Lawrence DS. A mechanistic design principle for protein tyrosine kinase sensors: application to a validated cancer target. Org Lett. 2008 Jan;10(2):301-304. doi: 10.1021/ol702675b.109. Tartari CJ, Gunby RH, Coluccia AM, Sottocornola R, Cimbro B, Scapozza L, Donella-Deana A, Pinna LA, Gambacorti-Passerini C. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J Biol Chem. 2008 Feb;283(7):3743-3750. doi: 10.1074/jbc.M706067200.

110. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res. 2008 May;6(5):751-759. doi: 10.1158/1541-7786.MCR-07-2001. 111. Puttini M, Redaelli S, Moretti L, Brussolo S, Gunby RH, Mologni L, Marchesi E, Cleris L, Donella-Deana A, Drueckes P, Sala E, Lucchini V, Kubbutat M, Formelli F, Zambon A, Scapozza L, Gambacorti-Passerini C. Characterization of compound 584, an Abl kinase inhibitor with lasting effects. Haematologica. 2008 May;93(5):653-661. doi: 10.3324/haematol.12212. 112. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008 Feb;111(3):1039-1043. doi: 10.1182/blood-2007-07-103523.113. Gambacorti-Passerini C . Part I: Milestones in personalised medicine--imatinib. Lancet Oncol. 2008 Jun;9(6):600. doi: 10.1016/S1470-2045(08)70152-9.114. Franceschino A, Tornaghi L, Benemacher V, Assouline S, Gambacorti-Passerini C. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. Haematologica. 2008 Feb;93(2):317-318.doi: 10.3324/haematol.11680.115. Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood. 2008 Jan;111(2):816-828. doi: 10.1182/blood-2007-05-090472.116. Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang JL, Hochhaus A, Khoury HJ, Brummendorf TH, Michallet M, Rege-Cambrin G, Gambacorti-Passerini C, Radich JP, Ernst T, Zhu C, Van Tornout JM, Talpaz M. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008 Dec;22(12):2176-2183. doi: 10.1038/leu.2008.221.117. Coluccia AM, Cirulli T, Neri P, Mangieri D, Colanardi MC, Gnoni A, Di Renzo N, Dammacco F, Tassone P, Ribatti D, Gambacorti-Passerini C, Vacca A. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood. 2008 Aug;112(4):1346-1356. doi: 10.1182/blood-2007-10-116590.118. Yasmeen A, Bismar TA, Dekhil H, Ricciardi R, Kassab A, Gambacorti-Passerini C, Al Moustafa AE. ErbB-2 receptor cooperates with E6/E7 oncoproteins of HPV type 16 in breast tumorigenesis. Cell Cycle. 2007 Dec;6(23):2939-2943. doi: 10.4161/cc.6.23.4949.119. Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, Hofstra RM, Barford D, Isacke CM. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem. 2007 Oct;282(40):29230-29240. doi: 10.1074/jbc.M703461200.120. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM,

Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007 Sep;117(9):2408-2421. doi: 10.1172/JCI31095.121. Gunby RH, Sala E, Tartari CJ, Puttini M, Gambacorti-Passerini C, Mologni L. Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy. Anticancer Agents Med Chem. 2007 Nov;7(6):594-611. doi: 10.2174/187152007784111340. 122. Gambacorti-Passerini CB , Tornaghi L, Marangon E, Franceschino A, Pogliani EM, D'Incalci M, Zucchetti M. Imatinib concentrations in human milk. Blood. 2007 Feb;109(4):1790. doi: 10.1182/blood-2006-08-039545.123. Gambacorti-Passerini C , Tornaghi L, Franceschino A, Piazza R, Corneo G, Pogliani E. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med. 2007 Jan;13(1):13-14; author reply 15-16. doi: 10.1038/nm0107-13b.124. Galietta A, Gunby RH, Redaelli S, Stano P, Carniti C, Bachi A, Tucker PW, Tartari CJ, Huang CJ, Colombo E, Pulford K, Puttini M, Piazza RG, Ruchatz H, Villa A, Donella-Deana A, Marin O, Perrotti D, Gambacorti-Passerini C. NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. Blood. 2007 Oct;110(7):2600-2609. doi: 10.1182/blood-2006-01-028647.125. Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjian H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, Druker BJ, Guilhot F. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer. 2007 Oct;110(7):1509-1519. doi: 10.1002/cncr.22936.126. Coluccia AM, Vacca A, Dunach M, Mologni L, Redaelli S, Bustos VH, Benati D, Pinna LA, Gambacorti-Passerini C. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 2007 Mar;26(5):1456-1466. doi: 10.1038/sj.emboj.7601485.127. Sala E, Mologni L, Cazzaniga S, Papinutto E, Gambacorti-Passerini C. A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer. Int J Biol Macromol. 2006 Aug;39(1-3):60-65. doi: 10.1016/j.ijbiomac.2006.01.006.128. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti-Passerini C. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006 Dec;66(23):11314-11322. doi: 10.1158/0008-5472.CAN-06-1199.129. Piazza RG, Magistroni V, Franceschino A, Andreoni F, Tornaghi L, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. Blood Cells Mol Dis. 2006 Sep-Oct;37(2):111-115. doi: 10.1016/j.bcmd.2006.06.002.130. Passoni L, Gallo B, Biganzoli E, Stefanoni R, Massimino M, Di Nicola M, Gianni AM, Gambacorti-Passerini C. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas. Haematologica. 2006 Jan;91(1):48-55.

131. Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M, Bain J, Cleris L, Redaelli S, Riva B, Formelli F, Scapozza L, Gambacorti-Passerini C. Inhibition of RET tyrosine kinase by SU5416. J Mol Endocrinol. 2006 Oct;37(2):199-212. doi: 10.1677/jme.1.01999.132. Gunby RH, Ahmed S, Sottocornola R, Gasser M, Redaelli S, Mologni L, Tartari CJ, Belloni V, Gambacorti-Passerini C, Scapozza L. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. J Med Chem. 2006 Sep;49(19):5759-5768. doi: 10.1021/jm060380k.133. Gambacorti-Passerini C . Prognostic variables in patients with chronic myeloid leukemia treated with imatinib. Haematologica. 2006 Feb;91(2):145a.134. Franceschino A, Tornaghi L, Piazza R, Pogliani E, Gambacorti Passerini C. Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease. Haematologica. 2006 Jun;91(6 Suppl):ECR14.135. Coluccia AM, Benati D, Dekhil H, De Filippo A, Lan C, Gambacorti-Passerini C. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res. 2006 Feb;66(4):2279-2286. doi: 10.1158/0008-5472.CAN-05-2057.136. Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med. 2006 Jun;354(24):2623-2624. doi: 10.1056/NEJMc053425.137. Assouline S, Benemacher V, Gambacorti-Passerini C. Simultaneous development of Philadelphia chromosome-positive and -negative leukemias in the same patient. Am J Hematol. 2006 Aug;81(8):646. doi: 10.1002/ajh.20629.138. Aloisi A, Di Gregorio S, Stagno F, Guglielmo P, Mannino F, Sormani MP, Bruzzi P, Gambacorti-Passerini C, Saglio G, Venuta S, Giustolisi R, Messina A, Vigneri P. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood. 2006 Feb;107(4):1591-1598. doi: 10.1182/blood-2005-05-2123.139. Piazza RG, Magistroni V, Gasser M, Andreoni F, Galietta A, Scapozza L, Gambacorti-Passerini C. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. Leukemia. 2005 Jan;19(1):132-134. doi: 10.1038/sj.leu.2403453.140. Piazza RG, Magistroni V, Franceschino A, Gambacorti Passerini C. Response to 'D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients' by Leguay et al. Leukemia 2005;19: 2333–2334. Doi:10.1038/sj.leu.2403994.141. Piazza RG, Magistroni V, Andreoni F, Franceschino A, Tornaghi L, Varella-Garcia M, Bungaro S, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C. Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients. Leukemia. 2005 Nov;19(11):1985-1987. doi: 10.1038/sj.leu.2403928.142. Perseghin P, Gambacorti-Passerini C, Tornaghi L, Dassi M, Pioltelli P, Parma M, Colnaghi F, Giudici G, Elli E, Fumagalli M, Ponchio L, Biondi A, Pogliani EM. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. Transfusion. 2005 Jul;45(7):1214-1220. doi: 10.1111/j.1537-2995.2005.00175.x.

143. Mologni L, Sala E, Riva B, Cesaro L, Cazzaniga S, Redaelli S, Marin O, Pasquato N, Donella-Deana A, Gambacorti-Passerini C. Expression, purification, and inhibition of human RET tyrosine kinase. Protein Expr Purif. 2005 May;41(1):177-185. doi: 10.1016/j.pep.2005.01.002.144. Gunby RH, Tartari CJ, Porchia F, Donella-Deana A, Scapozza L, Gambacorti-Passerini C. An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase. Haematologica. 2005 Jul;90(7):988-990.145. Gambacorti-Passerini C , Gasser M, Ahmed S, Assouline S, Scapozza L. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia. 2005 Jul;19(7):1267-1269. doi: 10.1038/sj.leu.2403775.146. Gambacorti-Passerini C . Gene expression analysis fails to identify patients with chronic myeloid leukemia who will achieve cytogenetic response to imatinib. Haematologica. 2005 Apr;90(4):434.147. Donella-Deana A, Marin O, Cesaro L, Gunby RH, Ferrarese A, Coluccia AM, Tartari CJ, Mologni L, Scapozza L, Gambacorti-Passerini C, Pinna LA. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry. 2005 Jun;44(23):8533-8542. doi: 10.1021/bi0472954.148. Coluccia AM, Gunby RH, Tartari CJ, Scapozza L, Gambacorti-Passerini C, Passoni L. Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. Expert Opin Ther Targets. 2005 Jun;9(3):515-532. doi: 10.1517/14728222.9.3.515.149. Gambacorti-Passerini C , Piazza R, Tornaghi L, Pilotti S, Pogliani E. Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment. J Natl Cancer Inst. 2004 Nov;96(22):1723-1724. doi: 10.1093/jnci/djh330.150. Gambacorti-Passerini C . Oncogenic tyrosine kinases. Cell Mol Life Sci. 2004; 61:(23):2895-2896. doi: 10.1007/s00018-004-4270-1.151. Coluccia AM, Perego S, Cleris L, Gunby RH, Passoni L, Marchesi E, Formelli F, Gambacorti-Passerini C. Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. Blood. 2004 Apr;103(7):2787-2794. doi: 10.1182/blood-2003-09-3144.152. Gambacorti–Passerini C . Imatinib mesylate associated with delayed hematopoietic recovery after concomitant chemotherapy-Response. Leukemia 2004;18: 887–888. doi:10.1038/sj.leu.2403314153. Ruchatz H, Puttini M, Cleris L, Pilotti S, Gambacorti-Passerini C, Formelli F. Effect of imatinib on haematopoietic recovery following idarubicin exposure. Leukemia. 2003 Feb;17(2):298-304. doi: 10.1038/sj.leu.2402800.154. Ruchatz H, Coluccia AM, Stano P, Marchesi E, Gambacorti-Passerini C. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Exp Hematol. 2003 Apr;31(4):309-315. doi: 10.1016/S0301-472X(03)00007-9. 155. Gambacorti-Passerini C . A human papillomavirus type 16 vaccine. N Engl J Med 2003; 348:1402-1405.doi: 10.1056/NEJM200304033481418.156. Passoni L, Gambacorti-Passerini C. ALK a novel lymphoma-associated tumor antigen for vaccination strategies. Leuk Lymphoma. 2003 Oct;44(10):1675-1681.

doi: 10.1080/1042819031000099625.157. Luksch R, Perotti D, Cefalo G, Gambacorti Passerini C, Massimino M, Spreafico F, Casanova M, Ferrari A, Terenziani M, Polastri D, Gambirasio F, Podda M, Bozzi F, Ravagnani F, Parmiani G, Fossati Bellani F. Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori. 2003 May-Jun;89(3):263-268. doi: 10.1177/030089160308900306.158. Gunby RH, Cazzaniga G, Tassi E, Le Coutre P, Pogliani E, Specchia G, Biondi A, Gambacorti-Passerini C. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia. Haematologica. 2003 Apr;88(4):408-415.. 159. Gambacorti-Passerini C B, Sala EA. Prostatectomy or watchful waiting in prostate cancer. N Engl J Med. 2003 Jan; 348:(2):170-171; author reply 170-171. doi: 10.1056/NEJM200301093480213. 160. Gambacorti-Passerini C B, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003 Feb;4(2):75-85. doi: 10.1016/S1470-2045(03)00979-3. 161. Gambacorti-Passerini C , Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, Alberti D, Corneo G, D'Incalci M. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res. 2003 Feb;9(2):625-632. 162. Gambacorti-Passerini C , Tornaghi L, Cavagnini F, Rossi P, Pecori-Giraldi F, Mariani L, Cambiaghi N, Pogliani E, Corneo G, Gnessi L. Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet. 2003 Jun;361(9373):1954-1956. doi: 10.1016/S0140-6736(03)13554-4.163. Gambacorti-Passerini C , Piazza R, D'Incalci M. Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels. Blood. 2003 Sep;102(5):1933-1934; author reply 1934-1935. doi: 10.1182/blood-2003-05-1629.164. Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C, Formelli F. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett. 2002 Jan;175(1):17-25. doi: 10.1016/S0304-3835(01)00718-2.165. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002 Mar;99(6):1928-1937. doi: 10.1182/blood.V99.6.1928.166. Luca Mologni, Carlo Gambacorti-Passerini. PNAs as novel cancer therapeutics. Letters in Peptide Science 2003; 10 (3–4): 297–308.doi: 10.1007/s10989-004-4909-7.167. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002 May;99(10):3530-3539.doi: 10.1182/blood.V99.10.3530.

168. Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA, Calabretta B. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet. 2002 Jan;30(1):48-58. doi: 10.1038/ng791.169. Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AM, Lemonnier FA, Kosmatopoulos K, Gambacorti-Passerini C. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood. 2002 Mar 15;99(6):2100-2106. doi: 10.1182/blood.V99.6.2100. 170. Mozziconacci MJ, Rosenauer A, Restouin A, Fanelli M, Shao W, Fernandez F, Toiron Y, Viscardi J, Gambacorti-Passerini C, Miller WH, Jr., Lafage-Pochitaloff M. Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones. Genes Chromosomes Cancer. 2002 Nov;35(3):261-270. doi: 10.1002/gcc.10117.171. le Coutre P, Kreuzer KA, Na IK, Lupberger J, Holdhoff M, Appelt C, Schwarz M, Muller C, Gambacorti-Passerini C, Platzbecker U, Bonnet R, Ehninger G, Schmidt CA. Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis. 2002 Jan-Feb;28(1):75-85. doi: 10.1006/bcmd.2002.0493 . 172. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E, International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002 Feb 28;346(9):645-652. doi: 10.1056/NEJMoa011573.173. Iervolino A, Santilli G, Trotta R, Guerzoni C, Cesi V, Bergamaschi A, Gambacorti-Passerini C, Calabretta B, Perrotti D. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Mol Cell Biol. 2002 Apr;22(7):2255-2266. doi: 10.1128/MCB.22.7.2255-2266.2002. 174. Gambacorti-Passerini C B, Rossi F, Verga M, Ruchatz H, Gunby R, Frapolli R, Zucchetti M, Scapozza L, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, D'Incalci M, Corneo G. Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. Blood Cells Mol Dis. 2002 May-Jun;28(3):361-372. doi: 10.1006/bcmd.2002.0526.175. Gambacorti-Passerini C , le Coutre P, Zucchetti M, D'Incalci M. Binding of imatinib by alpha(1)-acid glycoprotein. Blood. 2002 Jul;100(1):367-368; author reply 368-369. doi: 10.1182/blood-2002-02-0518.176. Gambacorti-Passerini C . Decrease of resistance to imatinib in leukaemia. Lancet; 2002 May;359:(9319):1777. doi: 10.1016/S0140-6736(02)08623-3.177. Mologni L, Marchesi E, Nielsen PE, Gambacorti-Passerini C. Inhibition of promyelocytic leukemia (PML)/retinoic acid receptor-alpha and PML expression in acute promyelocytic leukemia cells by anti-PML peptide nucleic acid. Cancer Res. 2001 Jul;61(14):5468-5473. 178. Hochhaus A, Kreil S, Corbin A, La Rosee P, Lahaye T, Berger U, Cross NC, Linkesch W, Druker BJ, Hehlmann R, Gambacorti-Passerini C, Corneo G, D'Incalci M. Roots of clinical resistance to STI-571 cancer therapy. Science. 2001 Sep;293(5538):2163. doi: 10.1126/science.293.5538.2163a. 179. Gambacorti-Passerini C , Barni R, Marchesi E, Verga M, Rossi F, Rossi F, Pioltelli P, Pogliani E, Corneo GM. Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained

from chronic myelogenous leukaemia patients in different stages of disease. Br J Haematol. 2001 Mar;112(4):972-974. doi: 10.1046/j.1365-2141.2001.02653.x.180. Gambacorti-Passerini C . Of nicks and time. N Engl J Med; 2001 Dec;345:(21):1576. doi: 10.1056/NEJM200111223452116.181. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000 Mar 1;95(5):1758-1766.182. Gambacorti-Passerini C , Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F, D'Incalci M. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst. 2000 Oct 18;92(20):1641-1650. doi: 10.1093/jnci/92.20.1641.183. Bertazzoli C, Marchesi E, Passoni L, Barni R, Ravagnani F, Lombardo C, Corneo GM, Pioltelli P, Pogliani E, Gambacorti-Passerini C. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients. Clin Cancer Res. 2000 May;6(5):1931-1935. 184. Pawelec G, Rees RC, Kiessling R, Madrigal A, Dodi A, Baxevanis C, Gambacorti-Passerini C, Masucci G, Zeuthen J. Cells and cytokines in immunotherapy and gene therapy of cancer. Crit Rev Oncog. 1999;10(1-2):83-127. 185. Mologni L, Nielsen PE, Gambacorti-Passerini C. In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid. Biochem Biophys Res Commun. 1999 Oct;264(2):537-543. doi: 10.1006/bbrc.1999.1548.186. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst. 1999 Jan;91(2):163-168. doi: 10.1093/jnci/91.2.163. 187. Fanelli M, Minucci S, Gelmetti V, Nervi C, Gambacorti-Passerini C, Pelicci PG. Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. Blood. 1999 Mar;93(5):1477-1481. 188. Wang ZG, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP, Jr., Pandolfi PP. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood. 1998 Sep;92(5):1497-1504.189. Ten Bosch GJ, Kessler JH, Blom J, Joosten AM, Gambacorti-Passerini C, Melief CJ, Leeksma OC. BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation. Br J Haematol. 1998 Dec;103(4):1109-1115. doi: 10.1046/j.1365-2141.1998.01115.x. 190. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst. 1998 Jan;90(2):124-133. doi: 10.1093/jnci/90.2.124.191. Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, Pelicci PG, Testi R. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood. 1998 Oct 1;92(7):2244-2251.

192. Mologni L, leCoutre P, Nielsen PE, Gambacorti-Passerini C. Additive antisense effects of different PNAs on the in vitro translation of the PML/RARalpha gene. Nucleic Acids Res. 1998 Apr;26(8):1934-1938. doi: 10.1093/nar/26.8.1934. 193. Gambacorti-Passerini C , le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo GM, Belotti D, Pogliani E, Lydon NB. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis. 1997 Dec;23(3):380-394. doi: 10.1006/bcmd.1997.0155.194. Gambacorti-Passerini C , Bertazzoli C, Dermime S, Scardino A, Schendel D, Parmiani G. Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers. Clin Cancer Res. 1997 May;3(5):675-683.195. Bertazzoli C, Marchesi E, Dermime S, Ravagnani F, Parmiani G, Gambacorti-Passerini C. HLA binding characteristics and generation of cytotoxic lymphocytes against peptides derived from oncogenic proteins. Tumori. 1997 Sep-Oct;83(5):847-855. doi: 10.1177/030089169708300515.196. Gianni M, Terao M, Gambacorti-Passerini C, Rambaldi A, Garattini E. Effects of 1,25-dihydroxy vitamin D3 on all-trans retinoic acid sensitive and resistant acute promyelocytic leukemia cells. Biochem Biophys Res Commun. 1996 Jul;224(1):50-56. doi: 10.1006/bbrc.1996.0983.197. Gambacorti-Passerini C , Mologni L, Bertazzoli C, le Coutre P, Marchesi E, Grignani F, Nielsen PE. In vitro transcription and translation inhibition by anti-promyelocytic leukemia (PML)/retinoic acid receptor alpha and anti-PML peptide nucleic acid. Blood. 1996 Aug;88(4):1411-1417.198. Dermime S, Bertazzoli C, Marchesi E, Ravagnani F, Blaser K, Corneo GM, Pogliani E, Parmiani G, Gambacorti-Passerini C. Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Clin Cancer Res. 1996 Mar;2(3):593-600.199. Benedetti L, Grignani F, Scicchitano BM, Jetten AM, Diverio D, Lo Coco F, Avvisati G, Gambacorti-Passerini C, Adamo S, Levin AA, Pelicci PG, Nervi C. Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase. Blood. 1996 Mar 1;87(5):1939-1950. 200. Gambacorti-Passerini C , Ott J, Bergen A. The human molecular genetics network. N Engl J Med. 1995 Dec;333(23):1573. doi: 10.1056/NEJM199512073332319.201. Dermime S, Grignani F, Rogaia D, Liberatore C, Marchesi E, Gambacorti-Passerini C. Acute promyelocytic leukaemia cells resistant to retinoic acid show further perturbation of the RAR alpha signal transduction system. Leuk Lymphoma. 1995 Jan;16(3-4):289-295. doi: 10.3109/10428199509049768.202. Dermime S, Barrett J, Gambacorti-Passerini C. The role of the immune system in anti-tumour responses. Potential for drug therapy. Drugs Aging. 1995 Oct;7(4):266-277. doi: 10.2165/00002512-199507040-00002. 203. Gambacorti-Passerini C , Hank JA, Albertini MR, Borchert AA, Moore KH, Schiller JH, Bechhofer R, Borden EC, Storer B, Sondel PM. A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer. J Immunother Emphasis Tumor Immunol. 1993 Jan;13(1):43-48. doi: 10.1097/00002371-199301000-00006. 204. Gambacorti-Passerini C , Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the

hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood. 1993 Mar;81(5):1369-1375. doi: 0006-4971/93/8105-0024S3.00/0.205. Gambacorti-Passerini C . Immunogenicity of fusion proteins. An example of tumor-specific/transformation-related antigens. Int J Clin Lab Res. 1993;23(4):186-191. doi: 10.1007/BF02592307.206. Dermime S, Grignani F, Clerici M, Nervi C, Sozzi G, Talamo GP, Marchesi E, Formelli F, Parmiani G, Pelicci PG, Gambacorti-Passerini C. Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein. Blood. 1993 Sep;82(5):1573-1577. doi: 0006-49 71/93/8205-0022$3.00/0. 207. Arienti F, Belli F, Rivoltini L, Gambacorti-Passerini C, Furlan L, Mascheroni L, Prada A, Rizzi M, Marchesi E, Vaglini M, et al. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunol Immunother. 1993 May;36(5):315-322. doi: 10.1007/BF01741170. 208. Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunol Immunother. 1992;34(4):241-251. doi: 10.1007/BF01741792.209. Arienti F, Gambacorti-Passerini C, Borin L, Rivoltini L, Orazi A, Pogliani EM, Corneo G, Parmiani G. Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules. Ann Oncol. 1992 Feb;3(2):155-162.210. Pogliani EM, Borin L, Gambacorti Passerini C, Lanzafame C, Corneo G. Early detection of relapse in acute non-lymphoblastic leukaemia patients by cancer procoagulant assay. Eur J Cancer. 1991;27(6):810-811. doi: 10.1016/0277-5379(91)90200-W.211. Gambacorti-Passerini C , Rivoltini L, Fizzotti M, Rodolfo M, Sensi ML, Castelli C, Orazi A, Polli N, Bregni M, Siena S, et al. Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells. Br J Haematol. 1991 Jun;78(2):197-205. doi: 10.1111/j.1365-2141.1991.tb04416.x.212. Gambacorti-Passerini C , Hank JA, Borchert A, Moore K, Malkovska V, Sondel P. In vivo effects of multiple cycles of recombinant interleukin-2 (IL2) on peripheral granulocyte-macrophage hematopoietic progenitors circulating in the blood of cancer patients. Tumori. 1991 Oct;77(5):420-422. doi: 10.1177/030089169107700509. 213. Rivoltini L, Gambacorti-Passerini C, Squadrelli-Saraceno M, Grosso MI, Cantu G, Molinari R, Orazi A, Parmiani G. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res. 1990 Sep;50(17):5551-5557.214. Gambacorti-Passerini C , Sondel PM. Problems, controversies, and perspectives on the clinical use of interleukin-2. Curr Opin Oncol. 1990 Dec;2(6):1139-1145. 215. Rivoltini L, Gambacorti-Passerini C, Supino R, Parmiani G. Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance. Int J Cancer. 1989 May;43(5):880-885. doi: 10.1002/ijc.2910430524.

216. Radrizzani M, Gambacorti-Passerini C, Parmiani G, Fossati G. Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells. Cancer Immunol Immunother. 1989;28(1):67-73. doi: 10.1007/BF00205803. 217. Gambacorti-Passerini C , Rivoltini L, Radrizzani M, Belli F, Sciorelli G, Ravagnani F, Galazka AR, Cascinelli N, Parmiani G. Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation. Cancer Res. 1989 Sep;49(18):5230-5234.218. Gambacorti Passerini C , Cortellaro M, Cofrancesco E, Boschetti C, Pogliani E, Alessio G, Semeraro N, Mussoni L, Donati MB. Possible mechanisms of fibrin deposition in the hypereosinophilic syndrome. Haemostasis. 1989;19(1):32-37. doi: 10.1159/000215886. 219. Cascinelli N, Belli F, Marchini S, Marolda R, Prada A, Sciorelli G, Villani F, Gambacorti-Passerini C, Galazka A, Parmiani G. A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patients. Tumori. 1989 Jun;75(3):233-244. doi: 10.1177/030089168907500309. 220. Parmiani G, Fossati G, Radrizzani M, Gambacorti-Passerini C, Marolda R, Cascinelli N. Potential therapeutic use of autologous human lymphocytes in metastatic melanoma: in vivo interleukin 2-activated peripheral blood lymphocytes and in vitro activated peripheral blood and tumor-infiltrating lymphocytes. Adv Exp Med Biol. 1988;233:453-458. 221. Gambacorti-Passerini C , Rivoltini L, Supino R, Rodolfo M, Radrizzani M, Fossati G, Parmiani G. Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes. Cancer Res. 1988 May;48(9):2372-2376. 222. Gambacorti-Passerini C , Rivoltini L, Supino R, Mariani M, Parmiani G. Differential lysis of melanoma clones by autologous recombinant interleukin 2-activated lymphocytes. Relationship with spontaneous resistance to doxorubicin (Dx). Int J Cancer. 1988 Oct;42(4):544-548. doi: 10.1002/ijc.2910420412.223. Gambacorti-Passerini C , Rivoltini L, Radrizzani M, Supino R, Mariani M, Parmiani G. Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2-activated lymphocytes (LAK). Cancer Metastasis Rev. 1988 Dec;7(4):335-345. doi: 10.1007/BF00051374.224. Gambacorti-Passerini C , Radrizzani M, Rivoltini L, Marchesi E, Ravagnani F, Sciorelli G, Cascinelli N, Parmiani G. A new procedure for large scale production and freezing of lymphokine activated killer (LAK) cells to be used in adoptive immunotherapy of cancer. Tumori. 1988 Oct;74(5):523-530. doi: 10.1177/030089168807400505.225. Gambacorti-Passerini C , Radrizzani M, Marolda R, Belli F, Sciorelli G, Galazka AR, Schindler JD, Cascinelli N, Parmiani G. In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2. Int J Cancer. 1988 May;41(5):700-706. doi: 10.1002/ijc.2910410511.226. Marolda R, Belli F, Prada A, Villani F, Gambacorti-Passerini C, Galazka A, Parmiani G, Cascinelli N. A phase I study of recombinant interleukin 2 in melanoma patients. Toxicity and clinical effects. Tumori. 1987 Dec;73(6):575-584. doi: 10.1177/030089168707300606.227. Gambacorti-Passerini C , Radrizzani M, Erba E, Fossati G, Parmiani G. Lysis by activated lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with mafosfamide. Cancer Res. 1987 May;47(10):2547-2552.

228. Parmiani G, Sensi ML, Balsari A, Colombo MP, Gambacorti-Passerini C, Grazioli L, Rodolfo M, Cascinelli N, Fossati G. Adoptive immunotherapy of cancer with immune and activated lymphocytes: experimental and clinical studies. Ric Clin Lab. 1986 Jan-Mar;16(1):1-20. doi: 10.1007/BF02886719.229. Mussoni L, Conforti G, Gambacorti-Passerini C, Alessio G, Pepe S, Vaghi M, Erba E, Amato G, Landoni F, Mangioni C, et al. Procoagulant and fibrinolytic activity of human ovarian carcinoma cells in culture. Eur J Cancer Clin Oncol. 1986 Apr;22(4):373-380. doi: 10.1016/0277-5379(86)90101-X.230. Gambacorti-Passerini C , Marolda R, Tona G, Sciorelli G, Fossati G, Cascinelli N, Parmiani G. Infusion of autologous alloactivated lymphocytes in melanoma patients: toxicity and immunologic monitoring. Tumori. 1986 Aug;72(4):383-388. doi: 10.1177/030089168607200407.231. Gambacorti Passerini C , Fossati G, Semeraro N, Donati MB, Gordon SG. Cancer procoagulant and haemostatic abnormalities in melanoma. Lancet. 1986 Apr;1(8486):920. doi: 10.1016/S0140-6736(86)91027-5.232. Fossati G, Anichini A, Taramelli D, Balsari A, Gambacorti-Passerini C, Kirkwood JM, Parmiani G. Immune response to autologous human melanoma: implication of class I and II MHC products. Biochim Biophys Acta. 1986 Dec;865(3):235-251. doi: 10.1016/0304-419X(86)90015-6.233. Donati MB, Gambacorti-Passerini C, Casali B, Falanga A, Vannotti P, Fossati G, Semeraro N, Gordon SG. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res. 1986 Dec;46(12 Pt 1):6471-6474.234. Balsari A, Marolda R, Gambacorti-Passerini C, Sciorelli G, Tona G, Cosulich E, Taramelli D, Fossati G, Parmiani G, Cascinelli N. Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study. Cancer Immunol Immunother. 1986;21(2):148-155. doi: 10.1007/BF00199863.235. Parmiani G, Fossati G, Taramelli D, Anichini A, Balsari A, Gambacorti-Passerini C, Sciorelli G, Cascinelli N. Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells. Cancer Metastasis Rev. 1985;4(1):7-26. doi: 10.1007/BF00047734.236. Curatolo L, Alessio G, Gambacorti Passerini C, Casali B, Morasca L, Semeraro N, Donati MB. Procoagulant activity of mouse and human cultured cells following various types of transformation. Int J Cancer. 1985 Mar;35(3):411-414. doi: 10.1002/ijc.2910350318.237. Lombardo A, Goi G, Gambacorti Passerini C, Barbieri MC, Colombo G, Rugarli C, Tettamanti G. Lysosomal glycohydrolases in normal T and non-T peripheral lymphocytes. Clin Chim Acta. 1984 Feb;137(1):67-75. doi: 10.1016/0009-8981(84)90313-9.

238. Gambacorti-Passerini C, Donati MB, Semeraro N, Cofrancesco E, Cortellaro M.

Monocyte procoagulant activity in hypereosinophilic syndrome. Lancet. 1983 Aug 20;2(8347):460-

1. IF 25.8

REVIEW ARTICLES

CARLO GAMBACORTI-PASSERINI M.D

R1. Gambacorti-Passerini C, Piazza R. Imatinib- A New tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. Jama Oncology 2015 March 12. doi:10.1001/jamaoncol.2015.50. Not available

R2. Gambacorti-Passerini C, Piazza R. How I treat newly diagnosed chronic myeloid leukemia in 2015. Am J Hematol. 2015 Feb;90(2):156-61. doi: 10.1002/ajh.23887. Epub 2014 Nov 24. IF 3.477

R3. Rusconi F, Piazza R, Vagge E, Gambacorti-Passerini C. Bosutinib: a review of preclinical and clinical studies in chronic myelogenous leukemia. Expert Opin Pharmacother. 2014 Apr;15(5):701-10. doi: 10.1517/14656566.2014.882898. Epub 2014 Jan 30. IF 3.085

R4. Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G, Jamieson C, Soverini S, Gambacorti-Passerini C, Hehlmann R, Martinelli G, Perrotti D, Scadden DT, Skorski T, Tefferi A, Mughal TI. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. Leuk Lymphoma. 2013 Jun;54(6):1151-8. doi: 10.3109/10428194.2012.745524. Epub 2012 Dec 10. IF 2.605

R5. Tartari CJ, Scapozza L, Gambacorti-Passerini C. The ALK gene, an attractive target for inhibitor development. Curr Top Med Chem. 2011;11(11):1406-19. IF 4.473

R6. Boschelli F, Arndt K, Gambacorti-Passerini C. Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia. Eur J Cancer. 2010 Jul;46(10):1781-9. doi: 10.1016/j.ejca.2010.02.032. IF 4.121

R7. Gunby RH, Sala E, Tartari CJ, Puttini M, Gambacorti-Passerini C, Mologni L. Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy. Anticancer Agents Med Chem. 2007 Nov;7(6):594-611. IF not available

R8. Coluccia AM, Gunby RH, Tartari CJ, Scapozza L, Gambacorti-Passerini C, Passoni L. Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. Expert Opin Ther Targets. 2005 Jun;9(3):515-32. IF 2.662

R9. Gambacorti-Passerini C. Oncogenic tyrosine kinases. Cell Mol Life Sci. 2004 Dec;61(23):2895-6. IF 4.655

R10. Passoni L, Gambacorti-Passerini C. ALK a novel lymphoma-associated tumor antigen for vaccination strategies. Leuk Lymphoma. 2003 Oct;44(10):1675-81. IF 1.559

R11. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003 Feb;4(2):75-85. IF 10.119

R12. Gambacorti-Passerini CB. A human papillomavirus type 16 vaccine. N Engl J Med. 348: 1402-5, 2003. IF 51.296

R13. Gambacorti-Passerini C, Sala EA. Prostatectomy or watchful waiting in prostate cancer. N Engl J Med.;348(2):170-1; 2003. IF 51.296

R14. Gambacorti-Passerini C. Of nicks and time. N Engl J Med. 2001 Nov 22;345(21):1576. IF 51.296

R15. Gambacorti-Passerini C, le Coutre P, Tassi E and Ruchatz H. Gene amplification the most likely mechanism of resistance to STI571 in LAMA84R cells. Blood, 96, 4003-4005, 2000. IF 10.37

R16. Gambacorti-Passerini C. Too many agencies spoil Euro research. Nature, 399, 101, 1999. IF 26.681

R17. Pawelec G, Rees RC, Kiessling R, Madrigal A, Dodi A, Baxevanis C, Gambacorti-Passerini C, Masucci G, Zeuthen J. Cells and cytokines in immunotherapy and gene therapy of cancer. Crit Rev Oncog. 1999;10(1-2):83-127. IF 3.281

R18. Dermime S, Barrett J, Gambacorti-Passerini C. The role of the immune system in anti-tumour responses. Potential for drug therapy. Drugs Aging. 1995 Oct;7(4):266-77. IF 2.2

R19. Gambacorti-Passerini C. Serum CD25 levels in cancer patients. Blood, 82, 326, 1993. IF 10.37

R20. Gambacorti-Passerini C. Immunogenicity of fusion proteins. An example of tumor-specific/transformation-related antigens. Int J Clin Lab Res. 1993;23(4):186-91. IF not available

R21. Gambacorti-Passerini C. Problems of European law. Nature, 356, 738, 1992. IF 26.681

R22. Gambacorti-Passerini C, Sondel PM. Problems, controversies, and perspectives on the clinical use of interleukin-2. Curr Opin Oncol. 1990 Dec;2(6):1139-45. IF 3.571

R23. Gambacorti-Passerini C, Rivoltini L, Radrizzani M, Supino R, Mariani M, Parmiani G. Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2-activated lymphocytes (LAK). Cancer Metastasis Rev. 1988 Dec;7(4):335-45. IF not available

R24. Fossati G, Anichini A, Taramelli D, Balsari A, Gambacorti-Passerini C, Kirkwood JM, Parmiani G. Immune response to autologous human melanoma: implication of class I and II MHC products. Biochim Biophys Acta. 1986 Dec 17;865(3):235-51. IF 0.931

ABSTRACTS

A 1. Renso R, Aroldi A, Pioltelli P, Gambacorti-Passerini C, Elli EM. LONG-TERM AND LOW-DOSE BUSULFAN IS SAFE AND EFFECTIVE IN ELDERLY PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA. HAEMATOLOGICA 2017;102:555-56.

A 2. Farina F, Ceccon M, Mori S, Verga L, Borin LM, Mologni L, Fontana D, Geeta G, Piazza R, Gambacorti-Passerini C. LONG-TERM EFFICACY AND SAFETY OF CRIZOTINIB IN RELAPSED ALK POSITIVE LYMPHOMA PATIENTS: CLINICAL AND BIOLOGICAL CORRELATES. HAEMATOLOGICA 2017;102:221-22.

A 3. Bruemmendorf TH, Gambacorti-Passerini C, Deininger M, Mauro MJ, Chuah C, Kim DW, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Cortes JE, Investigators BS . BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: INITIAL RESULTS FROM THE BFORE TRIAL. HAEMATOLOGICA 2017;102:152-52.

A 4. Silvestri G, Stramucci L, Ellis J, Yu J, Jason H, Neviani P, Marcucci G, Srutova K, Machova-Polakova K, Roy DC, Hokland P, Deininger M, Bhatia R, Gambacorti-Passerini C, Milojkovic D, Reid A, Livak F, Baer MR, Trotta R, Perrotti D. ROLE OF THE MSC-DERIVED EXOSOMAL AND ENDOGENOUS JAK2-SET/PP2A-B-CATENIN-MODULATOR MIR-300 IN LEUKEMIC STEM/PROGENITOR PROLIFERATION AND SURVIVAL IN CML. HAEMATOLOGICA 2016;101:181-81.

A 5. Mori S, le Coutre P, Abruzzese E, Martino B, Pungolino E, Elena C, Bergamaschi M, Assouline S, DiBona E, Gozzini A, Andrade M, Stagno F, Iurlo A, Luciani M, Tosetti R, Kim DW, Pirola A, Viltadi M, Bonanomi ML, Crivori P, Piazza R, Gambacorti-Passerini C. LATE RELAPSES, UP TO 45 MONTHS AFTER IMATINIB DISCONTINUATION: RESULTS FROM THE ISAV STUDY. HAEMATOLOGICA 2016;101:62-63.

A 6. Aroldi A, Mottadelli F, Carrer A, Colnaghi F, Pioltelli PE, Gambacorti-Passerini C, Elli EM. ANALYSIS OF CLINICAL PHENOTYPE AND OUTCOME IN CALR VERSUS JAK2 MUTATED OR TRIPLE-NEGATIVE ESSENTIAL THROMBOCYTEMIA. HAEMATOLOGICA 2016;101:555-56.

A 7. Silvestri G, Stramucci L, Ellis J, Yu J, Harb J, Neviani P, Marcucci G, Srutova K, Polakova KM, Roy DC, Hokland P, Deininger MW, Bhatia R, Gambacorti-Passerini C, Milojkovic D, Reid AG, Apperley JF, Livak F, Baer MR, Trotta R, Perrotti D. Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. BLOOD 2015;126(23).

A 8. Redaelli S, Ceccon M, Pirola A, Peronaci M, Gambacorti-Passerini C, Mologni L. Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma. BLOOD 2015;126(23).

A 9. Niro A, Piazza R, Merati G, Pirola A, Donadoni C, Fontana D, Redaelli S, Mezzatesta C, Renso R, Farina F, Rea D, Gambacorti-Passerini C. ETNK1 Is an Early Event and SETBP1 a Late Event in Atypical Chronic Myeloid Leukemia. BLOOD 2015;126(23).

A 10. Niro A, Piazza R, Merati G, Pirola A, Donadoni C, Fontana D, Redaelli S, Mezzatesta C, Renso R, Cecchetti C, Rea D, Gambacorti-Passerini C. CLONAL EVOLUTION ANALYSIS IDENTIFIES ETNK1 AS AN EARLY EVENT AND SETBP1 AS A LATE EVENT IN ATYPICAL CHRONIC MYELOID LEUKEMIA. HAEMATOLOGICA 2015;100:45-45.

A 11. Mori S, le Coutre P, Abruzzese E, Martino B, Pungolino E, Elena C, Pierri I, Assouline SE, D'Emilio A, Gozzini A, Ciraldo P, Stagno F, Iurlo A, Aroldi A, Luciani M, De Riso G, Dong-Wook K, Pirola A, Petroccione A, Bonanomi ML, Crivori P, Piazza R, Gambacorti-Passerini C. Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months. BLOOD 2015;126(23).

A 12. Mologni L, Ceccon M, Fontana D, Pirola A, Piazza R, Gambacorti-Passerini C. Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors. CANCER RESEARCH 2015;75.

A 13. Lipton JH, Cortes JE, Khoury HJ, Kantarjian HM, Kim DW, Schafhausen P, Zeremski M, Bardy-Bouxin N, Shapiro M, Leip E, Gambacorti-Passerini C, Brummendorf TH. Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic myeloid leukemia (CML) after prior imatinib (IM) failure. JOURNAL OF CLINICAL ONCOLOGY 2015;33(15).

A 14. le Coutre PD, Cortes JE, Kim DW, Pinilla-Ibarz J, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM. Ponatinib efficacy and safety in heavily pretreated leukemia patients (Pts) in the PACE trial at 3 years. Oncology Research and Treatment 2015;38:182-83.

A 15. Hochhaus A, Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Lustgarten S, Conlan M, Rivera VM, Guilhot F, Deininger MW, Hughes TP, Shah NP, Kantarjian HM. Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial. BLOOD 2015;126(23).

A 16. Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Lipton JH, Brummendorf TH, Noonan K, Matczak E, Leip E, Cortes JE. Long-term bosutinib (BOS) for Philadelphia Chromosome-Positive (Ph plus ) advanced (ADV) chronic myeloid leukemia (CML) after prior tyrosine kinase inhibitor (TKI) failure. JOURNAL OF CLINICAL ONCOLOGY 2015;33(15).

A 17. Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Lipton JH, Brummendorf TH, Noonan K, Matczak E, Leip E, Cortes JE. LONG-TERM BOSUTINIB FOR PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) ADVANCED CHRONIC MYELOID LEUKEMIA (CML) AFTER PRIOR TYROSINE KINASE INHIBITOR FAILURE. HAEMATOLOGICA 2015;100:440-41.

A 18. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Lustgarten S, Conlan M, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Kantarjian HM, Shah NP. Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study. BLOOD 2015;126(23).

A 19. Cortes J, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM. PONATINIB EFFICACY AND SAFETY IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 3-YEAR RESULTS OF THE PACE TRIAL. HAEMATOLOGICA 2015;100:64-64.

A 20. Cecchetti C, Piazza R, Pirola A, Magistroni V, Donadoni C, Mezzatesta C, Bianchi B, Borin LM, Fumagalli M, Gambacorti-Passerini C. NOVEL FUSIONS AND POINT MUTATIONS

DETECTED IN NEWLY DIAGNOSED AML PATIENTS BY RNA-SEQ IDENTIFY POTENTIAL NEW TREATMENT OPTIONS. HAEMATOLOGICA 2015;100:44-44.

A 21. Campiotti L, Suter MB, Gambacorti-Passerini C, Onida F, Guasti L, Grandi AM, Squizzato A. Tyrosin-Kinase Inhibitors Discontinuation in Patients with Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. BLOOD 2015;126(23).

A 22. Brummendorf TH, Cortes JE, Khoury HJ, Kantarjian HM, Kim DW, Schafhausen P, Zeremski M, Bardy-Bouxin N, Shapiro M, Leip E, Gambacorti-Passerini C, Lipton JH. LONG-TERM BOSUTINIB IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) AFTER PRIOR IMATINIB FAILURE. HAEMATOLOGICA 2015;100:232-32.

A 23. Abruzzese E, Foreman A, Gambacorti-Passerini C, Gentilini F, Liberati AM, Sica S, Alimena G. CYTOGENETIC AND MOLECULAR RESPONSES IN ITALIAN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN A PROSPECTIVE OBSERVATIONAL STUDY. HAEMATOLOGICA 2015;100:129-29.

A 24. Vigano I, Piazza R, Pirola A, Donadoni C, Vagge E, Spinelli R, Borin L, Rusconi F, Gambacorti-Passerini C. IDENTIFICATION OF SOMATIC MUTATIONS OR FUSIONS BY RNA-SEQUENCING IN ACUTE MYELOID LEUKEMIA. HAEMATOLOGICA 2014;99:17-17.

A 25. Redaelli S, Piazza R, Pirola A, Magistroni V, Schnittger S, Meggendorfer M, Cross NCP, Rea D, Gambacorti-Passerini C. Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia. BLOOD 2014;124(21).

A 26. Nicolini FE, Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hughes TP, Shah NP, Kantarjian HM, Hochhaus A. CLINICAL IMPACT OF DOSE MODIFICATION AND DOSE INTENSITY ON RESPONSE TO PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIAS. HAEMATOLOGICA 2014;99:334-34.

A 27. Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, Elena C, Pierri I, Assouline S, D'Emilio A, Cozzini A, Giraldo P, Stagno F, Iurlo A, Luciani M, De Riso G, Dong-Wook K, Pirola A, Petroccione A, D'Oria AL, Crivori P, Piazza R, Gambacorti-Passerini C. The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis. BLOOD 2014;124(21).

A 28. Mauro M, Gambacorti-Passerini C, Goldberg SL, Cortes JE, Khoury HJ, Michallet M, Paquette R, Simonsson B, Turner MP, Mohamed H, Subar M, Zyczynski T. Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY). BLOOD 2014;124(21).

A 29. Magistroni V, Piazza R, Sharma N, Parker W, Pirola A, Yeung D, Schreiber A, Wang P, Hamish SS, Dong-Wook K, Branford S, Gambacorti-Passerini C. IDENTIFICATION OF RECURRENT GENETIC ALTERATIONS ASSOCIATED WITH BLAST CRISIS TRANSFORMATION IN CHRONIC MYELOID LEUKEMIA. HAEMATOLOGICA 2014;99:510-11.

A 30. le Coutre PD, Kim DW, Pinilla-Ibarz J, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo D, Abruzzese E, Rea D, Baccarani M, Muller M, Gambacorti-Passerini C, Lustgarten S, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM, Cortes JE. PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME- POSITIVE (PH plus ) LEUKEMIAS RESISTANT OR INTOLERANT TO DASATINIB OR NILOTINIB, OR WITH THE T315I MUTATION: LONGER-TERM FOLLOW-UP OF THE PACE TRIAL. HAEMATOLOGICA 2014;99:334-34.

A 31. Hehlmann R, Cortes J, Gambacorti-Passerini C, Goldberg SL, Khoury HJ, Mauro M, Michallet M, Mohamed H, Powell T, Paquette R, Simonsson B, Subar M, Zyczynski T . TYROSINE KINASE INHIBITOR (TKI) SWITCHING: EXPERIENCE FROM SIMPLICITY, A PROSPECTIVE OBSERVATIONAL STUDY OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS IN CLINICAL PRACTICE. HAEMATOLOGICA 2014;99:328-29.

A 32. Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Mauro MJ, Michallet M, Paquette R, Simonsson B, Foreman A, Mohamed H, Subar M, Zyczynski TM. Cytogenetic and molecular testing in patients with chronic myeloid leukemia (CML) in a prospective observational study (SIMPLICITY). JOURNAL OF CLINICAL ONCOLOGY 2014;32(15).

A 33. Gambacorti-Passerini C, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P, Matczak EM, Leip E, Noonan K, Brummendorf TH, Cortes JE. Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study. BLOOD 2014;124(21).

A 34. Gambacorti-Passerini C, Kantarjian H, Khoury HJ, Brummendorf TH, Conlan MG, Wang K, Fly KD, Shapiro M, Lipton JH, Durand JB, Cortes JE. LONG-TERM ASSESSMENT OF CARDIAC TOXICITY IN PATIENTS WITH PH plus LEUKEMIAS TREATED WITH BOSUTINIB. HAEMATOLOGICA 2014;99:338-38.

A 35. Donadoni C, Piazza R, Fontana D, Parmiani A, Pirola A, Redaelli S, Signore G, Piazza V, Malcovati L, Spinelli R, Magistroni V, Gaipa G, Peronaci M, Morotti A, Panuzzo C, Saglio G, Elli EM, Usala E, Kim DW, Rea D, Zervakis K, Viniou NA, Symeonidis A, Becker H, Boultwood J, Campiotti L, Carrabba MG, Bignell GR, Papaemmanuil E, Campbell PJ, Cazzola M, Gambacorti-Passerini C. Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia. BLOOD 2014;124(21).

A 36. Cortes JE, Kim DW, Pinilla-Ibarz J, Le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM. Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. BLOOD 2014;124(21).

A 37. Cortes JE, Kantarjian HM, Khoury HJ, Brummendorf TH, Conlan MG, Wang KM, Fly KD, Shapiro M, Lipton JH, Durand JB, Gambacorti-Passerini C. Long-term evaluation of vascular toxicity in patients with Ph plus leukemias treated with bosutinib. JOURNAL OF CLINICAL ONCOLOGY 2014;32(15).

A 38. Cortes JE, Kantarjian H, Khoury HJ, Brummendorf TH, Conlan MG, Wang K, Fly KD, Shapiro M, Lipton JH, Durand JB, Gambacorti-Passerini C. LONG-TERM EVALUATION OF VASCULAR TOXICITY IN PATIENTS WITH PH plus LEUKEMIAS TREATED WITH BOSUTINIB. HAEMATOLOGICA 2014;99:336-37.

A 39. Ceccon M, Mologni L, Giudici G, Piazza R, Pirola A, Fontana D, Gambacorti-Passerini C. Mechanisms of resistance to the second-generation alk inhibitor ap26113 in human npm-alk-positive anaplastic large cell lymphoma cells. CANCER RESEARCH 2014;74(19).

A 40. Brummendorf TH, Cortes JE, Khoury HJ, Kantarjian HM, Kim DW, Schafhausen P, Zeremski M, Shapiro M, Leip E, Gambacorti-Passerini C, Lipton JH. Bosutinib As Second-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: 60-Month Update of a Phase 1/2 Study. BLOOD 2014;124(21).

A 41. Abruzzese E, Scortechini AR, Gugliotta G, Pierri I, Musolino C, Iurlo A, Mastrullo L, Caracciolo C, Orlandi E, Galimberti S, Salvucci M, Avanzini P, Sica S, Alimena G, Bocchia M, Pregno P, D'Emilio A, Gambacorti-Passerini C, Stagno F, Santorsola D, Castagnetti F, Perrotti AP, de Fabritiis P, Baccarani M. Gimema Registry of Conception/Pregnancy in Adult Patients Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). BLOOD 2014;124(21).

A 42. Redaelli S, Farina F, Stasia A, Ceccon M, Mologni L, Messa C, Guerra L, Giudici G, Sala E, Mussolin L, Deeren D, King MH, Steurer M, Ordemann R, Cohen A, Grube M, Bernard L, Chiriano G, Piazza R, Gambacorti-Passerini C. High Response Rates To Crizotinib In Advanced, Chemoresistant ALK plus Lymphoma Patients. BLOOD 2013;122(21).

A 43. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim DW, Boultwood J, Rossi F, Gaipa G, De Martini GP, Di Celle PF, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NC, Gambacorti-Passerini C. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. LEUKEMIA RESEARCH 2013;37:S34-S35.

A 44. Piazza R, Redaelli S, Valletta S, Pirola A, Spinelli R, Magistroni V, Kim DW, Cross NCP, Gambacorti-Passerini C. SETBP1 and CSF3R Mutations In Atypical Chronic Myeloid Leukemia. BLOOD 2013;122(21).

A 45. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van-Loo P, Pellagati A, Groves M, Cross N, Gambacorti-Passerini C, Green A, Boultwood J, Vyas P, Hellstrom-Lindberg E,

Bowen D, Cazzola M, Stratton MR, Campbell PJ. Clinical and biological implications of gene mutations in MDS. LEUKEMIA RESEARCH 2013;37:S9-S9.

A 46. Le Coutre PD, Kim DW, Pinilla-Ibarz J, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, Dipersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Lustgarten S, Yanase K, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Goldman JM, Shah NP, Kantarjian HM, Cortes JE. Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). BLOOD 2013;122(21).

A 47. Khoury HJ, Cortes JE, Kim DW, Pinilla-Ibarz J, Le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley J, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Lustgarten S, Yanase K, Kantarjian HM. Analysis of the cardiovascular risk profile of Ph plus leukemia patients treated with ponatinib. JOURNAL OF CLINICAL ONCOLOGY 2013;31(15).

A 48. Kantarjian HM, Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Goldman JM, Shah NP . Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. BLOOD 2013;122(21).

A 49. Hochhaus A, Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Deininger MW, Hughes TP, Goldman JM, Shah NP, Kantarjian HM, Guilhot F. Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. BLOOD 2013;122(21).

A 50. Gambacorti-Passerini C, Brummendorf TH, Cortes JE, Lipton JH, Kim DW, Leip E, Turnbull KW, Kantarjian HM, Khoury HJ. Evolution of bosutinib (BOS) toxicity in patients (pts) with Ph plus leukemia after resistance/intolerance to prior therapy. JOURNAL OF CLINICAL ONCOLOGY 2013;31(15).

A 51. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Goldman JM, Shah NP, Kantarjian HM. Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial. BLOOD 2013;122(21).

A 52. Brummendorf TH, Cortes JE, Khoury HJ, Kantarjian HM, Kim DW, Conlan MG, Leip E, Turnbull K, Gambacorti-Passerini C, Lipton JH. Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Resistance Or Intolerance To Imatinib: 48-Month Update. BLOOD 2013;122(21).

A 53. Stegelmann F, Mayer J, Warzocha K, Huguet F, Steegmann JL, Gambacorti-Passerini C, Lofgren C, Dejardin D, Hochhaus A. Dasatinib vs imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): DASISION European subpopulation analysis. Onkologie 2012;35:47-48.

A 54. Spinelli R, Piazza R, Pirola A, Valletta S, Rostagno R, Mogavero A, Marega M, Raman H, Gambacorti-Passerini C. A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data. Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). Volume 7548 LNBI2012. p 73-82.

A 55. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Pellagatti A, Groves MJ, Cross NCP, Gambacorti-Passerini C, Green AR, Boultwood J, Vyas P, Hellstrom-Lindberg E, Bowen D, Cazzola M, Stratton MR, Campbell P. High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations

and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic. BLOOD 2012;120(21).

A 56. Mauro MJ, Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Dorer DJ, Knickerbocker RK, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah N, Kantarjian HM, Grp PS. Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Treated with Ponatinib in the PACE Trial. BLOOD 2012;120(21).

A 57. Magistroni V, Sharma N, Piazza R, Harb JG, Spinelli R, Pirola A, Ellis J, Dong-Wook K, Perrotti D, Gambacorti-Passerini C. Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia. BLOOD 2012;120(21).

A 58. Kim DW, Cortes JE, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo D, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Goldman JM, Shah N, Kantarjian HM, Grp PS. Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial. BLOOD 2012;120(21).

A 59. Khoury HJ, Gambacorti-Passerini C, Kantarjian HM, Kim DW, Marin D, Dorlhiac-Llacer PE, Zaritskey A, Navarro J, Bullorsky EO, Assouline S, Leip E, Kelly V, Turnbull K, Besson N, Cortes JE. Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update. BLOOD 2012;120(21).

A 60. Kantarjian HM, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo D, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Goldman J, Shah N, Cortes JE, Grp PS . Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial. BLOOD 2012;120(21).

A 61. Hochhaus A, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo D, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hughes TP, Goldman JM, Shah N, Kantarjian HM, Cortes JE, Grp PS. Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph plus ) Leukemia: Results From the PACE Trial. BLOOD 2012;120(21).

A 62. Gambacorti-Passerini C, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Dong-Wook K, Boultwood J, Rossi F, Gaipa G, De Martini G, di Celle PF, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell P, Chase AJ, Tapper WJ, Cross NCP, Piazza R. Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia Abrogate an Ubiquitination Site and Dysregulate SETBP1 Protein Levels. BLOOD 2012;120(21).

A 63. Gambacorti-Passerini C, Lipton JH, Tee GY, Casado LF, Zaritskey A, le Coutre PD, Duvillie L, Pavlov D, Countouriotis AM, Byrne J. BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up. JOURNAL OF CLINICAL ONCOLOGY 2012;30(15).

A 64. Gambacorti-Passerini C, Brummendorf TH, Kim DW, Dyagil I, Kantarjian HM, Pavlov D, Gogat K, Duvillie L, Shapiro M, Cortes JE. Efficacy and Tolerability of Bosutinib and Imatinib in Older Versus Younger Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia-BELA Trial. BLOOD 2012;120(21).

A 65. Cortes JE, Kim DW, Pinilla-Ibarz J, Paquette R, le Coutre PD, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Rea D, Abruzzese E, Muller MC, Baccarani M, Gambacorti-Passerini C, Turner CD, Haluska FG, Kantarjian H. PACE: A pivotal phase II trial

of ponatinib in patients with CML and Ph plus ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. JOURNAL OF CLINICAL ONCOLOGY 2012;30(15).

A 66. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clarkson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah N, Kantarjian HM, Grp PS. A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. BLOOD 2012;120(21).

A 67. Cortes JE, Khoury HJ, Lipton JH, Gambacorti-Passerini C, Brummendorf TH, Kim DW, Leip E, Kelly V, Besson N, Turnbull K, Kantarjian HM. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. BLOOD 2012;120(21).

A 68. Cortes JE, Kantarjian HM, Kim DW, Turkina AG, Shen ZX, Khoury HJ, Brummendorf TH, Schafhausen P, Vellenga E, Pasquini R, Mathews V, Masszi T, Durrant S, Porkka K, Leip E, Kelly V, Besson N, Gambacorti-Passerini C. Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update. BLOOD 2012;120(21).

A 69. Brummendorf TH, Kantarjian HM, Gambacorti-Passerini C, Guilhot F, Akard L, Doshi V, Lipton JH, Pavlov D, Gogat K, Duvillie L, Shapiro M, Cortes JE. Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study. BLOOD 2012;120(21).

A 70. Brummendorf TH, Gambacorti-Passerini C, Schafhausen P, Khoury HJ, Hochhaus A, Kindler T, Fischer T, Besson N, Leip E, Kelly V, Cortes JE. Efficacy and safety of bosutinib (BOS) for Philadelphia chromosome-positive (Ph plus ) leukemia in older versus younger patients (pts). JOURNAL OF CLINICAL ONCOLOGY 2012;30(15).

A 71. af Gennas GB, Mologni L, Ahmed S, Rajaratnam M, Marin O, Lindholm N, Viltadi M, Gambacorti-Passerini C, Scapozza L, Yli-Kauhaluoma J. Design, synthesis and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors. Abstracts of Papers of the American Chemical Society 2012;243.

A 72. Spinelli R, Piazza R, Raman H, Pirola A, Valletta S, Stasia A, Gambacorti-Passerini C. Identification of Novel Point Mutations in Splicing Sites by the Integration of Exome and RNA Sequencing Data in Myeloproliferative Diseases. BLOOD 2011;118(21):1055-56.

A 73. Piazza R, Valletta S, Pirola A, Raman H, Spinelli R, Cross NCP, Cecchetti C, Sortino Z, Gambacorti-Passerini C. Whole-Exome Sequencing of 8 Atypical Chronic Myeloid Leukaemia Patients. BLOOD 2011;118(21):1647-47.

A 74. Mughal TI, Radich JP, van Etten RA, Quintás-Cardama A, Skorski T, Ravandi F, Deangelo DJ, Gambacorti-Passerini C, Martinelli G, Tefferi A. Chronic myeloid leukemia 2011: Successes, challenges, and strategies-Proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. AMERICAN JOURNAL OF HEMATOLOGY 2011;86(9):811-19.

A 75. Khoury HJ, Cortes JE, Gambacorti-Passerini C, Kim DW, Zaritskey A, Hochhaus A, Leip E, Besson N, Kelly V, Brummendorf TH. Activity of Bosutinib by Baseline and Emergent Mutation Status in Philadelphia Chromosome Positive Leukemia Patients with Resistance or Intolerance to Other Tyrosine Kinase Inhibitors. BLOOD 2011;118(21):53-54.

A 76. Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brummendorf TH, Porkka K, Martinelli G, Durrant S, Leip E, Besson N, Kelly V, Gambacorti-Passerini C. Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors. BLOOD 2011;118(21):1187-88.

A 77. Gambacorti-Passerini C, Valletta S, Stasia A, Leeksma A, Sharma N, Rizzo C, Pogliani EM, Pirola A, Piazza R. CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis. BLOOD 2011;118(21):1178-78.

A 78. Gambacorti-Passerini C, Cortes JE, Kim D, Kantarjian H, Khattry N, Lipton JH, Powell C, Harris P, Countouriotis AM, Brummendorf TH. Bosutinib (BOS) versus imatinib (IM) in patients

(pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up. JOURNAL OF CLINICAL ONCOLOGY 2011;29(15).

A 79. Gambacorti-Passerini C, Cortes JE, Harris P, Powell C, Countouriotis A, Kantarjian HM. Safety and Management of Toxicities in the BELA Trial of Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. BLOOD 2011;118(21):732-32.

A 80. Gambacorti-Passerini C, Antolini L, Piazza R, Guilhot F, Deininger M, Fava C, Nagler A, Morra E, Abruzzese E, D'Emilio A, Stagno F, le Coutre PD, Monroy RH, Santini V, Pane F, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Pavesi F, Puttini M, Rizzo C, Dilda I, Mori S, Kim DW, Valsecchi MG. Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years. BLOOD 2011;118(21):1608-08.

A 81. Cortes JE, Maru A, De Souza CAA, Guilhot F, Duvillie L, Powell C, Countouriotis A, Gambacorti-Passerini C. Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia - BELA Trial: 24-Month Follow-up. BLOOD 2011;118(21):210-11.

A 82. Cortes JE, Kim DW, Pinilla-Ibarz J, Le Coutre PD, Chuah C, Nicolini FE, Paquette R, Apperley JF, DiPersio JF, Khoury HJ, Rea D, Talpaz M, DeAngelo DJ, Abruzzese E, Baccarani M, Mueller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Turner CD, Rivera VM, Clackson T, Haluska F, Kantarjian HM, Grp PS. Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation. BLOOD 2011;118(21):52-53.

A 83. Brummendorf TH, Cortes JE, Kantarjian H, Gambacorti-Passerini C, Baccarani M, Kim D, Zaritskey A, Navarro J, Rapoport A, Dorlhiac-Llacer PE, Milone J, Zanichelli M, Besson N, Leip E, Kelly V, Khoury HJ. Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL). JOURNAL OF CLINICAL ONCOLOGY 2011;29(15).

A 84. Redaelli S, Mologni L, Rostagno R, Piazza R, Viltadi M, Wise S, Flynn D, Gambacorti-Passerini C. A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036. BLOOD 2010;116(21):1391-91.

A 85. Khoury HJ, Kim DW, Zaritskey A, Gambacorti-Passerini C, Hochhaus A, Navarro J, Rapoport AP, Dorlhiac-Llacer PE, Zanichelli M, Kelly V, Besson N, McMullan T, Kantarjian HM, Cortes JE . Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib. BLOOD 2010;116(21):391-91.

A 86. Gambacorti-Passerini CB, Dilda I, Giudici G, Perego A, Pavesi F, Guerra L, Borin L, Casaroli I, Fedele M, Verga L, Pogliani EM. Clinical Activity of Crizotinib In Advanced, Chemoresistant ALK plus Lymphoma Patients. BLOOD 2010;116(21):1185-85.

A 87. Gambacorti-Passerini C, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L, Malhotra H, Goh YT, Wang JY, Gogat K, Cortes J. An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. BLOOD 2010;116(21):95-96.

A 88. Gambacorti-Passerini C, Khoury HJ, Pinczowsld H, Masszi T, Kim DW, Zanichelli M, Martinelli G, Kelly V, Besson N, McMullan T, Brumrnendorf TH, Cortes JE. Clinical Activity of Bosutinib by Mutational Status In Patients with Previously Treated Philadelphia Chromosome-positive Leukemias. BLOOD 2010;116(21):1407-08.

A 89. Gambacorti-Passerini C, Cortes JE, Khoury HJ, Baccarani M, Kantarjian H, Chandy M, Besson N, Wang J, Arkin S, Brummendorf T. Safety and efficacy of bosutinib in patients with AP and CML and ph plus ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200. JOURNAL OF CLINICAL ONCOLOGY 2010;28(15).

A 90. Gambacorti-Passerini C, Cortes J, Zaritskey A, Bullorsky E, Navarro J, Khoury H, Besson N, McMullan T, Arkin S, Brummendorf T. BOSUTINIB FOR THIRD-LINE TREATMENT OF CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) FOLLOWING RESISTANCE OR INTOLERANCE TO IMATINIB (IM) AND DASATINIB (D). Haematologica-the Hematology Journal 2010;95:57-58.

A 91. Cortes JE, Kantarjian H, Brummendorf T, Khoury HJ, Kim D, Turkina A, Volkert A, Wang J, Arkin S, Gambacorti-Passerini C. Safety and efficacy of bosutinib (SKI-606) in patients (pts) with

chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM). JOURNAL OF CLINICAL ONCOLOGY 2010;28(15).

A 92. Coluccia AML, De Leo S, de Luca E, Reddiconto G, Palama I, Redaelli S, De Matteis S, Gambacorti-Passerini C, Dini L, Maffia M. Deregulated Activity and Localization of Glycogen Synthase Kinase 3 beta In Chronic Myeloid Leukemia Progenitors: Role In Leukemia Maintenance and Targeted Therapy. BLOOD 2010;116(21):521-21.

A 93. Brummendorf T, Cortes J, Turkina A, Masszi T, Assouline S, Durrant S, Volkert A, Wang J, Arkin S, Gambacorti-Passerini C. SAFETY AND EFFICACY OF SECOND-LINE BOSUTINIB (SKI-606) IN IMATINIB RESISTANT OR INTOLERANT CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML). Haematologica-the Hematology Journal 2010;95:468-68.

A 94. Tartari C, Donadoni C, Manieri E, Mologni L, Gambacorti-Passerini C. Dissection of the RET/betacatenin interaction in the thyroid cancer line TPC1. CANCER RESEARCH 2009;69.

A 95. Magistroni V, Sanselicio S, Mologni L, Reid J, Gariboldi M, Gambacorti-Passerini C. Role of different ERG forms in cellular transformation. CANCER RESEARCH 2009;69.

A 96. Lock RB, Bachmann PS, Piazza RG, Davies C, James M, Wong NC, Bhadri VA, Mogavero A, Magistroni V, Gambacorti-Passerini C, Saffery R, Craig JM, Pimanda JE, Marshall GM. Epigenetic Silencing of the Pro-Apoptotic Bim Gene in Glucocorticoid Poor-Responsive Pediatric Acute Lymphoblastic Leukemia, and Its Reversal by Histone Deacetylase Inhibition. BLOOD 2009;114(22):387-88.

A 97. Kim DW, Antolini L, Mahon FX, Guilhot F, Deininger M, Saglio G, Nagler A, Rambaldi A, Morra E, Abruzzese E, Di Raimondo F, le Coutre P, Monroy RH, Durosinmi MA, Leeksma O, Pane F, Miglietta S, Kweon IY, Reiffers J, Valsecchi MG, Gambacorti-Passerini C. Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients. BLOOD 2009;114(22):865-66.

A 98. Deininger M, Mahon FX, Guilhot F, Saglio G, le Coutre P, Nagler A, D'Emilio A, Stagno F, Morra E, Piccin A, Assouline SE, Abruzzese E, Santini V, Pane F, Giraldo P, Antolini L, Valsecchi MG, Gambacorti-Passerini C. Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib. BLOOD 2009;114(22):454-55.

A 99. Saglio G, Dombret H, Rea D, Corm S, Cortes J, Kim DW, Garzon FT, Paliwal P, Baccarani M, Martinelli G, Gambacorti-Passerini C. DASATINIB EFFICACY IN PATIENTS WITH IMATINIB-RESISTANT/-INTOLERANT CHRONIC MYELOID LEUKEMIA IN BLAST PHASE: 24-MONTH DATA FROM THE START PROGRAM. Haematologica-the Hematology Journal 2008;93:349-49.

A 100. Gambacorti-Passerini C, Pogliani EM, Baccarani M, Martinelli G, Kantarjian HM, Chandy M, Khoury HJ, Kim DW, Brummendorf TH, Arkin S, Cortes J. Bosutinib (SKI-606) Demonstrates Clinical Activity and is Well Tolerated in Patients with AP and BP CML and Ph plus ALL. BLOOD 2008;112(11):402-02.

A 101. Gambacorti-Passerini C, Kim DW, Mahon FX, Saglio G, Pane F, Guilhot F, Deininger MWN, Nagler A, Rambaldi A, Morra E, Antolini L, Kweon IY, Reiffers J, Tornaghi L, Valsecchi MG . Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients. BLOOD 2008;112(11):401-02.

A 102. Gambacorti-Passerini C, Kantarjian HM, Baccarani M, Porkka K, Turkina A, Zaritskey AY, Agarwal S, Hewes B, Khoury HJ. Activity and tolerance of bosutinib in patients with AP and BP CML and Ph plus ALL. JOURNAL OF CLINICAL ONCOLOGY 2008;26(15).

A 103. Gambacorti-Passerini C, Cortes J, Kantarjian H, Kim D, Turkina A, Fischer T, Cervantes F, Agarwal S, Hewes B, Brummendorf TH. BOSUTINIB (SKI-606) SHOWS HIGH TOLERABILITY AND CLINICAL ACTIVITY IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIAS. Haematologica-the Hematology Journal 2008;93:160-61.

A 104. Cortes J, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Shen ZX, Brummendorf TH, Chandy M, Arkin S, Gambacorti-Passerini C. Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph plus Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib. BLOOD 2008;112(11):401-01.

A 105. Gambacorti-Passerini C, Kantarjian H, Bruemmendorf T, Martinelli G, Baccarani M, Fischer T, Pogliani EM, Hewes B, Volkert ADG, Bardy-Bouxin N, Cortes J. Bosutinib (SKI-606) demonstrates

clinical activity and is well tolerated among patients with AP and BPCML and Ph plus ALL. BLOOD 2007;110(11):146A-46A.

A 106. Galietta A, Gunby RH, Redaelli S, Bachi A, Piazza RG, Villa A, Pogliani EM, Gambacorti-Passerini C. NPM/ALK binds and phosphorylates the RNA/DNA binding protein PSF in anaplastic large cell lymphoma. Haematologica-the Hematology Journal 2007;92:48-49.

A 107. Eiring AM, Neviani P, Anthanam R, Oaks JJ, Chang JS, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D. Requirement of the E2F3 transeription factor for BCR/ABL leukemogenesis. BLOOD 2007;110(11):18A-18A.

A 108. Cortes J, Bruemmendorf T, Kantarjian H, Khoury J, Rosti G, Fischer T, Tornaghi L, Hewes B, Martin EC, Gambacorti-Passerini C. Efficacy and safety of Bosutinib,(SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML). BLOOD 2007;110(11):225A-25A.

A 109. Brummendorf T, Cortes J, Kantarjian H, Martinelli G, Liu D, Fischer T, Hewes B, Volkert ADG, Abbas R, Gambacorti-Passerini C. Bosutinib (SKI-606) exhibits clinical activity in patients with philadelphia chromosome positive CML or all who failed imatinib. Haematologica-the Hematology Journal 2007;92:116-16.

A 110. Gunby R, Ahmed S, Zambon A, Gasser M, Bertola L, Porchia F, Tartari C, Sottocornola R, Donella A, Goekjian P, Scapozza L, Gambacorti-Passerini C. Rational design of inhibitors of the anaplastic lymphoma kinase. European Journal of Pharmaceutical Sciences 2006;28:S26-S26.

A 111. Gambacorti-Passerini C. Tyrosine kinases and cancer therapy. European Journal of Pharmaceutical Sciences 2006;28:S3-S3.

A 112. Ahmed S, Gunby RH, Gambacorti-Passerini C, Scapozza L. Homology modelling, structure-based ligand design and experimental validation of candidate inhibitors on anaplastic lymphoma kinase (ALK). European Journal of Pharmaceutical Sciences 2006;28:S24-S24.

A 113. Perseghin P, Gambacorti-Passerini C, Tornaghi L, Pioltelli P, Dassi M, Elli E, Fumagalli M, Pogliani E. PBSC collection following G-CSF mobilisation in CML patients treated with imatinib mesylate. Bone Marrow Transplantation 2004;33:S148-S48.

A 114. Passoni L, Gallo B, Massimino M, DiNicola M, Passerini CG, Gambacorti-Passerini C. ALK is a lymphoma antigen triggering an in vivo long lasting memory response. Tissue Antigens 2004;64(4):382-82.

A 115. Gunby RH, Sottocornola R, Gasser M, Scapozza L, Gambacorti-Passerini C. Generation and verification of a three-dimensional model of the ALK kinase domain: ALK - A "supermutant" of Abl. BLOOD 2004;104(11):952A-53A.

A 116. Cazzaniga G, Corradi B, Piazza R, Soverini S, Martinelli G, Gambacorti-Passerini C, Biondi A. Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment. BLOOD 2004;104(11):548A-48A.

A 117. Piazza R, Magistroni V, Tornaghi L, Andreoni F, Bungaro S, Cazzaniga G, Biondi A, Pogliani E, Varella-Garcia M, Corneo G, Gambacorti-Passerini C. Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR). BLOOD 2003;102(11):319B-19B.

A 118. Coluccia AML, Perego S, Cleris L, Gunby RH, Passoni L, Marchesi E, Formelli F, Gambacorti-Passerini C. Bcl-X-L downregulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. BLOOD 2003;102(11):226A-26A.

A 119. Talpaz M, Silver RT, Druker BJ, Paquette R, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, O'Brien SG, Deininger MW, Hochhaus A, Ottmann OG, Gratwohl A, Tura S, Baccarani M, Stone RM, Reiffers J, Bolton AE, Gathmann I. Imatinib (STI571, Gleevec (TM)) achieves prolonged survival in patients with accelerated phase Ph plus chronic myeloid leukemia (CML-AP): Up to 36 months follow-up of a phase II study. BLOOD 2002;100(11):163A-63A.

A 120. Kantarjian HM, Sawyer CL, Hochhaus A, Guilhot F, Schiffer CA, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman JM, Fischer T, Reiffers J, O'Brien S, Miller CB, Tallman MS, Brown RA, Silver RT, Loughran TP, Gratwohl A, Mandelli F, So C, Zoellner U, Hensley ML, Druker BJ. Imatinib (Gleevec (TM)) results in sustained hematologic and cytogenetic responses among chronic-phase chronic myeloid leukemia (CML) failing interferon-alpha (IFN) - up to 31-month follow-up of 454 patients on phase II study. BLOOD 2002;100(11):94A-94A.

A 121. Talpaz M, Silver RT, Druker B, Paquette R, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Reese SF, Kantarjian HM, Ford JM. Gleevec (TM) (formerly STI571): An active drug in patients with Ph plus chronic myeloid leukemia in accelerated phase - Updated results of a phase II study. BLOOD 2001;98(11):845A-45A.

A 122. Ruchatz H, Puttini M, Cleris L, Formelli F, Pilotti S, Gambacorti-Passerini C. Co-administration of STI571 and idarubicin increases the sensitivity to cytotoxic treatment in vitro and in vivo. BLOOD 2001;98(11):101A-02A.

A 123. Perrotti D, Trotta R, Cesi V, Santilli G, Guerzoni C, Gambacorti-Passerini C, Calabretta B. Shuttling hnRNPs as regulators of BCR/ABL leukemogenic potential. BLOOD 2001;98(11):142A-42A.

A 124. Le Coutre P, Kreuzer KA, Lupberger J, Na IK, Holdhoff M, Appelt C, Schwarz M, Muller C, Gambacorti-Passerini C, Platzbecker U, Ehninger G, Schmidt CA. Alpha-1 acid glycoprotein levels in patients with chronic myeloid leukemia during treatment with STI571: Determination of plasma protein and mRNA levels during the first 13 weeks of therapy. BLOOD 2001;98(11):309A-09A.

A 125. Kantarjian HM, Sawyers CL, Hochhaus A, Guilhot F, Schiffer CA, Deininger MW, Gambacorti-Passerini C, Stone RM, Goldman J, Fischer T, Rosamilia M, Zoellner U, Resta D, Capdeville R, Druker BJ. Gleevec (TM)(imatinib mesylate) induced hematologic and cytogenetic responses confirmed and expanded in patient's with chronic myeloid leukemia (CML) - A phase II study update. BLOOD 2001;98(11):845A-45A.

A 126. Deininger MWN, Schafer K, Sayer H, Russel N, Peschel C, Gratwohl A, Goldman J, Hochhaus A, Guilhot F, Gambacorti-Passerini C, O'Brian S, Arcese W, Kolb H, AlAli H, Hegenbart U, Lange T, Capdeville R, Niederwieser D, Ebmt, Investigators STI. Successful allogeneic transplantation after treatment of blast crisis CML with STI571. Bone Marrow Transplantation 2001;27:S37-S38.

A 127. Passoni L, Gallo B, Marchesi E, Scardino A, Bertazzoli C, Gambacorti-Passerini C. In vitro induction of primary HLA class I-restricted immune response against ALK kinase. BLOOD 2000;96(11):338A-38A.

A 128. Martinelli GG, Amabile MM, Giannini BB, Montefusco VV, Testoni NN, De Vivo AA, Bonifazi FF, Ottaviani EE, Saglio GG, Terragna CC, Buonamici SS, Soverini SS, Gambacorti-Passerini C, Russo DD, Trabacchi EE, Bassi SS, Rosti GG, Baccarani MM, Tura SS . Predictive value of quantitative real-time evaluation of molecular response in CML patients treated with alpha-IFN. BLOOD 2000;96(11):737A-37A.

A 129. Gambacorti-Passerini C, Zucchetti M, Cleris L, Rossi F, Pogliani E, Corneo G, Formelli F, D'Incalci M. Alpha 1 acid glycoprotein (AGP) binds to STI571 and alters its tissue distribution and intracellular concentrations. BLOOD 2000;96(11):98A-98A.

A 130. Gambacorti-Passerini C, Verga M, Rossi F, Tornaghi L, Bungaro S, Ruchatz H, Rossi F, Pioltelli P, Pogliani E, Garattini E, Capdeville R, D'Incalci M, Corneo G. STI571 administered to chronic myeloid leukemia (CML) patients inhibits cell proliferation, induces apoptosis and initially causes partial inhibition of BCR/ABL autophosphorylation. BLOOD 2000;96(11):345A-45A.

A 131. Drabkin HA, Stano P, Gambacorti-Passerini C. Gene expression changes in WNT pathway components caused by STI571 in chronic mieloid leukemia (CML) cells sensitive or resistant to it. BLOOD 2000;96(11):674A-74A.

A 132. Gambacorti-Passerini C, Varella-Garcia M, Barni R, Tassi E, Cabrita G, Passoni L, Marchesi E, Supino R, le Coutre P. Induction of resistance to the abelson inhibitor STI571 (CGP57148B) in human BCR/ABL plus leukemic cells through gene amplification. BLOOD 1999;94(10):101A-01A.

A 133. le Coutre P, Cleris L, Marchesi E, Formelli F, Gambacorti-Passerini C. Eradication of BCR/ABL(+) leukemic cells in nude mice by the tyrosine-kinase inhibitor CGP57148B is dependent on the initial tumor load. BLOOD 1998;92(10):628A-28A.

A 134. Cazzaniga G, Le Coutre P, Zecevic M, Specchia G, Rambaldi A, Corneo GM, Pogliani E, Liso V, Biondi A, Gambacorti-Passerini C. Low frequency of ETV6(TEL)-PDGFR beta hybrid mRNA in Chronic Myelomonocytic Leukemia (CMML). BLOOD 1998;92(10):250B-51B.

A 135. Munari L, Silvani A, Gambacorti Passerini C, Radrizzani M, Parmiani G, Boiardi A . Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme. Journal of Neurosurgical Sciences 1990;34(3-4):283-88.